AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and Equipment
CystadenocarcinomaCystadenocarcinoma, MucinousCystadenomaCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousCystadenoma, MucinousAppendiceal NeoplasmsMucoceleCystsPyonephrosisMixed Tumor, MesodermalOvarian NeoplasmsBiliary Tract NeoplasmsCystadenoma, PapillaryParotid NeoplasmsBarium SulfatePseudomyxoma PeritoneiBile Ducts, IntrahepaticBile Duct NeoplasmsRetroperitoneal NeoplasmsPancreatic NeoplasmsTomography, X-Ray ComputedSalivary Gland NeoplasmsPancreatectomyHydroxy AcidsPancreaticoduodenectomy
Cystadenocarcinoma
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Cystadenocarcinoma, Mucinous
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Cystadenoma
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Cystadenocarcinoma, Papillary
An adenocarcinoma in which the tumor elements are arranged as finger-like processes or as a solid spherical nodule projecting from an epithelial surface.
Cystadenocarcinoma, Serous
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
Cystadenoma, Mucinous
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Appendiceal Neoplasms
Tumors or cancer of the APPENDIX.
Mucocele
A retention cyst of the salivary gland, lacrimal sac, paranasal sinuses, appendix, or gallbladder. (Stedman, 26th ed)
Cysts
Any fluid-filled closed cavity or sac that is lined by an EPITHELIUM. Cysts can be of normal, abnormal, non-neoplastic, or neoplastic tissues.
Pyonephrosis
Distention of KIDNEY with the presence of PUS and suppurative destruction of the renal parenchyma. It is often associated with renal obstruction and can lead to total or nearly total loss of renal function.
Mixed Tumor, Mesodermal
A sarcoma of the body of the uterus arising in older women, composed of more than one mesenchymal tissue, especially including striated muscle cells. It is associated with previous pelvic radiation exposure in 20% of patients. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1702)
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Biliary Tract Neoplasms
Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.
Cystadenoma, Papillary
A benign neoplasm of the ovary.
Parotid Neoplasms
Tumors or cancer of the PAROTID GLAND.
Barium Sulfate
A compound used as an x-ray contrast medium that occurs in nature as the mineral barite. It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation shield.
Pseudomyxoma Peritonei
A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)
Bile Ducts, Intrahepatic
Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.
Bile Duct Neoplasms
Tumors or cancer of the BILE DUCTS.
Retroperitoneal Neoplasms
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Tomography, X-Ray Computed
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Salivary Gland Neoplasms
Tumors or cancer of the SALIVARY GLANDS.
Pancreatectomy
Surgical removal of the pancreas. (Dorland, 28th ed)
Hydroxy Acids
Organic compounds containing both the hydroxyl and carboxyl radicals.
Pancreaticoduodenectomy
The excision of the head of the pancreas and the encircling loop of the duodenum to which it is connected.

Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. (1/526)

The primary element in the cAMP signal transduction pathway is the cAMP-dependent protein kinase (PKA). Expression of the RIalpha subunit of type I PKA is elevated in a variety of human tumours and cancer cell lines. The purpose of this study was to assess the prognostic importance of RIalpha expression in patients with ovarian cancer. We have evaluated the expression of RIalpha in a panel of human ovarian tumours (n = 40) and five human ovarian cancer cell lines using quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis. The human ovarian cell lines OAW42 and OTN14 express high endogenous levels of RIalpha mRNA and protein (at significantly higher mRNA levels than high tissue expressors, P < 0.05). The ovarian cell line A2780 expresses low endogenous levels of RIalpha mRNA and protein (also at higher mRNA levels than low tissue expressors, P < 0.05). Quantitative RT-PCR revealed no significant difference in RIalpha mRNA expression between different ovarian histological subtypes in this study. No associations were found between RIalpha mRNA expression and differentiation state. RIalpha mRNA expression was significantly associated with tumour stage (P = 0.0036), and this remained significant in univariate analysis (P = 0.0002). A trend emerged between RIalpha mRNA expression levels and overall survival in univariate analysis (P = 0.051), however, by multivariate analysis, stage remained the major determinant of overall survival (P = 0.0001). This study indicates that in ovarian epithelial tumours high RIalpha mRNA expression is associated with advanced stage disease. RIalpha expression may be of predictive value in ovarian cancer and may be associated with dysfunctional signalling pathways in this cancer type.  (+info)

The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour progression. (2/526)

The CCAAT/enhancer binding protein (C/EBP) family of transcription factors is involved in metabolism and differentiation of cells, especially in rodent liver cells and adipocytes. Their roles in vivo and in particular during pathophysiological conditions in humans are largely unknown. We have investigated the presence of C/EBPalpha, -beta, -delta and -zeta in normal ovaries and in epithelial ovarian tumours of different stages. Immunohistochemical experiments demonstrated that C/EBPalpha and C/EBPbeta were preferentially expressed in epithelial/tumour cells irrespective of stage or grade of the tumour. C/EBPbeta was located in the nuclei of the cells, in contrast to C/EBPalpha, which was present only in the cytoplasm of these cells. The nuclear localization of C/EBPbeta indicates an active role of this transcription factor in tumour cells, whereas the cytoplasmic distribution suggests a more passive function of C/EBPalpha. C/EBPdelta and -zeta demonstrated a more diverse distribution with predominant localization to epithelial cells, but stromal distribution was also noted. The intracellular distribution was confined to both the nucleus and the cytoplasm for C/EBPdelta and -zeta. Western blotting demonstrated that C/EBPalpha, -beta, -delta and -zeta were present in a majority of the samples. The amount of C/EBPbeta increased markedly with malignancy, i.e. with degree of dedifferentiation, while the other members of the C/EBP family displayed a more constant expression level. These results demonstrate an association between the expression of members of the C/EBP family and the formation of epithelial ovarian tumours, with C/EBPbeta as a potential marker for these tumours. As C/EBPbeta is known to be expressed during proliferation of cells in vitro, it may participate in the proliferative process of ovarian epithelial tumour cells in vivo and play a central role in tumour progression.  (+info)

Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: correlation with up-regulation in epithelial ovarian cancer. (3/526)

Abnormalities in the function of receptor tyrosine kinases (RTKs) have been demonstrated to be important in the pathogenesis of cancer. H-Ryk, a new member of the RTK family, is an unusual RTK in that it is catalytically inactive because of amino acid substitutions of conserved residues in the catalytic domain. We show by immunohistochemistry that it is expressed in the epithelium, stroma, and blood vessels of normal tissues. Evaluation of a panel of 33 primary ovarian tumors (2 benign, 8 borderline, and 23 malignant) was performed. H-Ryk was overexpressed in borderline and malignant ovarian tumors. In serous and clear cell subtypes, there was increased expression in the epithelium, stroma, and blood vessels. Consistent with this observation, overexpression of H-Ryk in the mouse fibroblast cell line NIH3T3 induces anchorage-independent growth and tumorigenicity in nude mice. This implies that overexpression of the receptor can be transforming and may therefore be significant in the pathogenesis of ovarian cancer.  (+info)

Borderline ovarian tumours in Vaud, Switzerland: incidence, survival and second neoplasms. (4/526)

Between 1976 and 1996, 176 borderline ovarian tumours were registered in the Cancer Registry of the Swiss canton of Vaud, corresponding to an age-adjusted incidence (world standard) of 2.7 in 100,000. Incidence rose from 1.7 per 100,000 during 1976-81 to 2.7 per 100,000 during 1987-91, and then levelled off; 58% of cases were serous and 41% mucinous. Relative survival was 94% at 10 years; 18 second neoplasms were observed, compared with 10.3 expected, and there was a significant excess of invasive ovarian cancers (four observed, including three synchronous, compared with 0.4 expected).  (+info)

Three dimensional ultrasound and power doppler in assessment of uterine and ovarian angiogenesis: a prospective study. (5/526)

AIM: To determine whether three-dimensional power Doppler can improve the recognition of pelvic tumor morphology and angiogenesis. METHODS: Using this technique we analyzed 180 adnexal masses and 110 uterine lesions. Tumor volume, morphology, and vascularity were evaluated in each patient. Irregular and randomly dispersed vessels with complex branching depicted by comprehensive three dimensional display were suggestive of pelvic malignancy, while linear-like vascular morphology, single vessel arrangement and regular branching were typical for benign structures. RESULTS: Addition of qualitative analysis of vascular architecture of adnexal tumor to morphological parameters reached 96.15% sensitivity and 98.73% specificity. When endometrial lesions were prospectively analyzed, sensitivity and specificity were 91.67% and 98.49%, respectively. Because the lowest positive predictive value of 16.67% was obtained for myometrial lesions, this method should not be advised for their eva luation. CONCLUSION: Good results achieved by three dimensional ultrasound can be explained by improved recognition of the pelvic lesion anatomy, characterization of the surface features, detection of the tumor infiltration, and precise depiction of the size and volume. Three dimensional power Doppler imaging can detect structural abnormalities of the malignant tumor vessels, such as arteriovenous shunts, microaneurysms, tumoral lakes, disproportional calibration, coiling, and dichotomous branching. Therefore it enhances and facilitates the morphologic and functional evaluation of both benign and malignant pelvic tumors.  (+info)

Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas*. (6/526)

Most of the ovarian cancers originate from the ovarian surface epithelium derived from the coelomic mesothelium. The Met proto-oncogene encodes a transmembrane tyrosine kinase receptor (Met) that has the capacity to regulate cell proliferation and differentation and it is activated by hepatocyte growth factor. Trisomy of chromosome 7 and Met protein overexpression have been were observed in ovarian carcinomas, the papillary renal cancers and other solid tumors. Frequent mutations of Met proto-oncogene have been found in hereditary papillary renal cancer (HPRC) and most of the mutations are located in the tyrosine kinase domain. The aim of this study to perform a mutation analysis of exons 17 19 of Met proto-oncogene in epithelial ovarian tumors (EOTs). We have examined 24 tumor samples from patients, operated with EOTs. Mutation was detected in exon 18 in only one sample of 24 EOTs. Our results indicate that mutations located in the Met proto-oncogene is not a common event in EOT. It is not clear whether the mutation plays a role in the tumorigenesis or progression of EOT or not.  (+info)

Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. (7/526)

The purpose of this study was to investigate the frequency of p53 overexpression in the primary ovarian tumors of patients with stages II and III serous borderline tumors (SBTs) and to determine the relationship between p53 overexpression and risk of progression/recurrence and survival. Of 112 patients with stages II-IV SBTs, paraffin-embedded tissue from the primary ovarian tumor was available in 68 cases. Immunohistochemical staining for p53 was performed. Clinical information was abstracted from the medical records. The major end points selected for analysis were time to progression/relapse, disease-free survival, overall survival, and cause-specific survival. Univariate and multivariate regression analyses were also performed. The median patient age was 37 years (range, 17-67 years). Twenty-two patients had stage II disease, and 46 had stage III disease. The mean follow-up time was 105 months. Nineteen patients (28%) had either disease progression (1 patient) or relapse (18 patients). Eleven patients died: 10 patients died of their tumor, and 1 patient died of other causes. Thirteen cases (19%) had positive immunostaining for p53. Overexpression of p53 was significantly associated with an increased probability of progression/recurrence (P = 0.005) and a decreased overall survival (P = 0.012). After adjusting for age, International Federation of Gynecology and Obstetrics (FIGO) stage, the presence of residual tumor, and the presence of invasive implants, patients whose tumors overexpressed p53 had a 4-fold increased risk of progression/ recurrence. Similarly, women whose tumor overexpressed p53 had an approximately 6-fold increased risk of death. p53 overexpression in the ovarian tumors of patients with stage II and III SBTs is significantly associated with increased probability of relapse and decreased overall survival. This information should provide better prognostic data to patients and their families and allow us to select patients who might benefit from postoperative treatment.  (+info)

Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. (8/526)

Allelic deletions of multiple chromosome 17q loci in sporadic ovarian cancer of epithelial origin suggest that inactivation of tumor suppressor gene(s) in these regions may be important for ovarian tumorigenesis. To further define the pattern of allelic imbalance in epithelial ovarian tumors of different histologies, a PCR-based assay was used to assess loss of heterozygosity (LOH) of polymorphic markers representative of TP53, BRCA1, NME1 and GH1, and region 17q23-25. LOH was observed for at least one marker in 68% of malignant tumors (n=60) and in 18% tumors of borderline malignancy (n=11), but not in benign tumors (n=5). The highest frequency of LOH in malignant tumors (64%) was observed with D17S801 on 17q25. Ten of 39 malignant ovarian tumors displaying LOH of at least one 17q marker, displayed a LOH pattern enabling the determination of a minimal region of overlapping deletion defined by D17S795 and D17S801. One borderline tumor also displayed an interstitial LOH pattern that overlapped this 17q25 minimal region of deletion. The histologies of malignant tumors displaying a pattern indicative of interstitial 17q deletions were of the endometrioid, clear cell and mucinous epithelial types. As the minimal region of overlap defined by these tumors overlap regions deleted in malignant tumors of all histologic types, and in a tumor of borderline malignancy, the 17q25-tumor suppressor may be implicated in the development of all types of epithelial ovarian tumors.  (+info)

GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2020 Jan 11;:109539 Authors: El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G Abstract High-grade serous ovarian carcinoma (HGSOC) is the mos...
https://medworm.com/759806239/gata3-as-a-master-regulator-for-interactions-of-tumor-associated-macrophages-with-high-grade-serous-/
Malignant Ovarian Serous Tumor - My Cancer Genome
There are 5 clinical trials for malignant ovarian serous tumor, of which 5 are open and 0 are completed or closed. Of the trials that contain malignant ovarian serous tumor as an inclusion criterion, 1 is phase 1 (1 open), 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open). BRCA1 and BRCA2 are the most frequent gene inclusion criteria for malignant ovarian serous tumor clinical trials [3]. ...
https://www.mycancergenome.org/content/disease/malignant-ovarian-serous-tumor/
TP53 Gene Mutation Found in 80% of High Grade Ovarian Serous Carcinomas; TP53 Not Directly Involved In The Development of Drug...
The TP53 gene mutation frequency in ovarian serous carcinomas has been reported to range between 50% and 80%. A research team working at the The Sidney Kimmel Comprehensive Cancer Center of The Johns Hopkins Medical Institutions (Johns Hopkins) made several important findings regarding TP53 gene mutations with respect to high grade ovarian serous carcinoma, as reported in the International Journal of Gynecological Cancer. Ovarian serous carcinoma is the most common tumor subtype within the epithelial ovarian cancer histological classification.. According to the Johns Hopkins research team, a stringent analysis of the TP53 gene using purified epithelial tumor samples has not been performed to accurately assess the TP53 gene mutation frequency and its correlation to tumor histologic grade. The research team assessed the TP53 gene mutational profile in a relatively large series of high-grade (53 primary tumors and 18 recurrent tumors) and 13 low-grade ovarian serous tumors. All samples were ...
https://libbyshope.com/2008/07/21/tp53-gene-mutation-found-in-80-of-high-grade-ovarian-serous-carcinomas-tp53-not-directly-involved-in-the-development-of-drug-resistance/
Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis<...Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis<...
TY - JOUR. T1 - Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. AU - Espinosa, Inigo. AU - Catasus, Lluis. AU - Canet, Belén. AU - DAngelo, Emanuela. AU - Mũoz, Josefina. AU - Prat, Jaime. PY - 2011/6/1. Y1 - 2011/6/1. N2 - Gene expression profiling is an important tool to evaluate genetic heterogeneity in carcinomas and is useful to develop expression-based classifications for many types of cancer, as well as markers of disease outcome. In this study, we have investigated the expression profile of 22 genes involved in the PI3K-AKT pathway in 26 high-grade ovarian carcinomas (19 serous and 7 clear cell carcinomas). Unsupervised hierarchical clustering divided high-grade ovarian carcinomas into three groups. Although all clear cell carcinomas clustered in one group, high-grade serous carcinomas were segregated into two separate groups with different prognosis (P=0.05). High expression of CASP3, XIAP (X-linked inhibitor of ...
https://portalrecerca.uab.cat/en/publications/gene-expression-analysis-identifies-two-groups-of-ovarian-high-gr
Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than...Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than...
The TP53 mutation frequency in ovarian serous carcinomas has been reported to range between 50% and 80%, but a stringent analysis of TP53 using purified epithelial samples has not yet been performed to accurately assess the mutation frequency and to correlate it with the histologic grade. The purpose of this study was to assess the TP53 mutational profile in a relatively large series of high-grade (53 primary and 18 recurrent) and 13 low-grade ovarian serous tumors using DNA isolated from affinity-purified tumor cells and to correlate it with in vitro drug resistance. All samples were affinity purified, and the tumor DNA was analyzed for TP53 mutations in exons 4-9. In vitro drug resistance assays to carboplatin, cisplatin, paclitaxel, and taxotere were performed on the same tumor samples and correlated with the TP53 mutation status. TP53 mutations were detected in 57 (80.3%) of 71 high-grade carcinomas and in one (7.8%) of 13 low-grade serous tumors (an invasive low-grade serous carcinoma). The ...
https://ijgc.bmj.com/content/18/3/487
Dishevelled family proteins in serous ovarian carcinomas: A clinicopathologic and molecular studyDishevelled family proteins in serous ovarian carcinomas: A clinicopathologic and molecular study
Dishevelled family proteins (DVL1, DVL2 and DVL3) are cytoplasmic mediators involved in canonical and non-canonical Wnt signaling that are important for embryonic development. Since Wnt signaling promotes cell proliferation and invasion, its increased activation is associated with cancer development as well. To get deeper insight into the behavior of Dishevelled proteins in cancer, we studied their expression in serous ovarian carcinomas [both low- (LGSC) and high-grade (HGSC)], and HGSC cell lines OVCAR5, OVCAR8 and OVSAHO. DVL protein expression in serous ovarian carcinomas tissues was analyzed using immunohistochemistry while DVL protein and mRNA expressions in HGSC cell lines were analyzed using western blot and quantitative real-time PCR. DVL1 protein expression was significantly higher in LGSC compared with normal ovarian tissue, while DVL3 was overexpressed in both LGSC and HGSC. DVL2 and DVL3 protein expression was higher in HGSC cell lines when compared with normal control cell line ...
https://quspace.qu.edu.qa/handle/10576/12343
Uterine Serous CarcinomaUterine Serous Carcinoma
Uterine serous carcinoma is a rare and highly aggressive variant of endometrial cancer. Uterine serous carcinoma accounts for 10% of all endometrial cancer; however, it carries the poorest prognosis, with 5-year survival rates as low as 55%. Whole-exome sequencing studies have recently reported c-Myc gene amplification in a large ...
https://www.cancer-research-network.com/category/endometrial-cancer/uterine-serous-carcinoma/
High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma | BMC Cancer | Full TextHigh expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma | BMC Cancer | Full Text
NAD(P)H:quinone oxidoreductase (NQO1) is a flavoprotein that catalyzes two-electron reduction and detoxification of quinones and its derivatives. NQO1 catalyzes reactions that have a protective effect against redox cycling, oxidative stress and neoplasia. High expression of NQO1 is associated with many solid tumors including those affecting the colon, breast and pancreas; however, its role in the progression of ovarian carcinoma is largely undefined. This study aimed to investigate the clinicopathological significance of high NQO1 expression in serous ovarian carcinoma. NQO1 protein expression was assessed using immunohistochemical (IHC) staining in 160 patients with serous ovarian carcinoma, 62 patients with ovarian borderline tumors and 53 patients with benign ovarian tumors. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect NQO1 mRNA expression levels. The correlation between high NQO1 expression and clinicopathological features of ovarian carcinoma was evaluated by
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1271-4/metrics
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. - Cancer Epidemiology Unit (CEU)
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This roadmap for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.
https://www.ceu.ox.ac.uk/publications/572958
Molecular Characterization of an Intact p53 Pathway Subtype in High-Grade Serous Ovarian CancerMolecular Characterization of an Intact p53 Pathway Subtype in High-Grade Serous Ovarian Cancer
High-grade serous ovarian cancer (HGSOC) is the most aggressive histological type of epithelial ovarian cancer, which is characterized by a high frequency of somatic TP53 mutations. We performed exome analyses of tumors and matched normal tissues of 34 Japanese patients with HGSOC and observed a substantial number of patients without TP53 mutation (24%, 8/34). Combined with the results of copy number variation analyses, we subdivided the 34 patients with HGSOC into subtypes designated ST1 and ST2. ST1 showed intact p53 pathway and was characterized by fewer somatic mutations and copy number alterations. In contrast, the p53 pathway was impaired in ST2, which is characterized by abundant somatic mutations and copy number alterations. Gene expression profiles combined with analyses using the Gene Ontology resource indicate the involvement of specific biological processes (mitosis and DNA helicase) that are relevant to genomic stability and cancer etiology. In particular we demonstrate the presence of a
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0114491
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with th …
https://pubmed.ncbi.nlm.nih.gov/26493647/?dopt=Abstract
Preservation of stemness in high-grade serous ovarian cancer organoids requires low Wnt environment - EGA European Genome...Preservation of stemness in high-grade serous ovarian cancer organoids requires low Wnt environment - EGA European Genome...
High-grade serous ovarian cancer (HGSOC) likely originates from the fallopian tube (FT) epithelium, but advanced stages are mostly found outside the FT. We used ex-vivo cultures of HGSOC and knock-out of tumor suppressors in FT organoids to study changes in epithelial cells and niche requirements for normal and transformed FT cells. We found that transformed cells require BMP signaling and are growth arrested in Wnt rich medium. A SureSelectXT Automation Custom Capture Library (Agilent) target enrichment panel was designed. The enrichment panel comprised all coding exons of 121 genes associated with ovarian cancer. Capture was performed according to the manufacturers instructions using an NGS Workstation Option B (Agilent) for automat... (Read more) ...
https://ega-archive.org/studies/EGAS00001003821
TBX2 expression is associated with platinum‑sensitivity of ovarian serous carcinomaTBX2 expression is associated with platinum‑sensitivity of ovarian serous carcinoma
The effective treatment of ovarian serous carcinoma remains a major challenge because of the recurrence of platinum-resistant tumors. The mechanism of platinum-resistance may involve decreased cellular uptake caused by abnormalities of transporters, intracellular cisplatin inactivation (e.g., caused by glutathione), and increased DNA repair (18). However, no available therapy prevents platinum-resistance.. TBX2 is overexpressed by numerous human cancers (7-14). TBX2 may serve as a prognostic factor of breast cancer (7,9), melanoma (8), gastric cancer (10), prostate cancer (11), laryngeal squamous cell carcinoma (12), and non-small cell lung cancer (14). TBX2 is associated with resistance to therapeutic drugs such as cisplatin and doxorubicin (15,16), and TBX2 therefore may serve as a therapeutic target.. One report shows that chromosome 17q12-q24 harbors strong candidates for ovarian tumorigenesis, such as LASP1 (17q12), TGF11 (17q21.32), MUL (17q23.2), TBX2 (17q23.2), AXIN2 (17q24.3), and GRB2 ...
https://www.spandidos-publications.com/10.3892/ol.2017.7719
Events Archive - ISGyPEvents Archive - ISGyP
Dr. Natalie Banet moderates the discussion of studies pertinent to the practice of Gynecological Pathology, led by pathology trainees. Articles to be covered: Zarei S, et al. Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma. Am J Surg Pathol. 2020;44(3):316-328. Seidman JD, et al. Intratumoral Heterogeneity Accounts for Apparent Progression of Noninvasive Serous Tumors to Invasive Low-grade Serous Carcinoma: A Study of 30 Low-grade Serous Tumors of the Ovary…. ...
https://isgyp.ca/live-events/list/?tribe_event_display=past
Plus itPlus it
High-grade serous ovarian carcinoma (HGSOC) is a lethal disease for which improved screening and treatment strategies are urgently required. Progress in these areas has been impeded by our poor understanding of HGSOC pathogenesis. The vast majority of ovarian cancer research is been based on the hypothesis that HGSOC develops from ovarian surface epithelial cells. However, recent studies suggest that , 50% of high-grade serous carcinomas involving the ovary likely arose from secretory cells of the fallopian tube epithelium. Consequently, current ovarian-based experimental models of HGSOC are inadequate in representing the full spectrum of the disease. The aim of our study was to develop the first experimental model of fallopian tube secretory epithelial cell (FTSEC) transformation and to use this model to answer three basic questions: 1) Can FTSECs be transformed in vitro?, 2) What genetic alterations are capable of transforming FTSECs?, and 3) Do transformed FTSECs give rise to high-grade ...
http://cancerres.aacrjournals.org/content/71/8_Supplement/1588
Plus itPlus it
Ovarian cancer accounts for 5% of all female cancer-related deaths, more than any other reproductive cancer. Of the various histological subtypes, high-grade serous carcinoma is the most common. Mutations in BRCA1/BRCA2, which are associated with familial predisposition, are present in 10% of cases, while TCGA data demonstrates that P53 is mutated in 96% of high-grade serous ovarian carcinomas. In addition to aberrant P53 expression, severe aneuploidy with a near polyploid number of chromosomes is the only other genetic abnormality associated with these tumors. Ploidy changes occur early in tumor development, suggesting that they play a crucial role in oncogenic transformation. Furthermore, severe aneuploidy is associated with poor clinical outcome in patients, presumably due to its role in treatment resistance.. We used an in vitro cell culture model derived from ovarian cystadenomas, the benign counterparts of ovarian carcinomas, to investigate the molecular events leading to such ploidy ...
http://cancerres.aacrjournals.org/content/74/19_Supplement/2387
Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study
Objective: The purpose of this study was to investigate the prognostic value of lymph node ratio (LNR) in patients with stage III ovarian high-grade serous carcinoma (HGSC). Methods: A multicenter, retrospective department database review was performed to identify patients with ovarian HGSC at 6 gynecologic oncology centers in Turkey. A total of 229 node-positive women with stage III ovarian HGSC who had undergone maximal or optimal cytoreductive surgery plus systematic lymphadenectomy followed by paclitaxel plus carboplatin combination chemotherapy were included. LNR, defined as the percentage of positive lymph nodes (LNs) to total nodes recovered, was stratified into 3 groups: LNR1 (,10%), LNR2 (10%,= LNR,50%), and LNR3 (,= 50%). Kaplan-Meier method was used to generate survival data. Factors predictive of outcome were analyzed using Cox proportional hazards models. Results: Thirty-one women (13.6%) were classified as stage IIIA1, 15 (6.6%) as stage IIIB, and 183 (79.9%) as stage IIIC. The ...
http://dspace.baskent.edu.tr:8080/xmlui/handle/11727/3125
Benign and Low Grade Serous Epithelial Tumors: Recent Developments and Diagnostic Problems. - Semantic ScholarBenign and Low Grade Serous Epithelial Tumors: Recent Developments and Diagnostic Problems. - Semantic Scholar
This review focuses on recent advances in the area of low-grade ovarian serous neoplasia with emphasis on key diagnostic criteria, differential diagnosis, and disease classification based on current understanding of low-grade serous carcinogenesis. Despite considerable controversy surrounding serous tumors of low malignant potential (S-LMP) or borderline tumors, there have been great strides in our understanding of the serous group of borderline and malignant pelvic epithelial neoplasms in the past decade. Most S-LMP have a favorable prognosis, but recurrences and progression to carcinoma occur, sometimes following a protracted clinical course. Pathologic risk factors vary, but the extraovarian implant status is the most important predictor for progressive disease. Progression of S-LMP usually takes the form of low-grade serous carcinoma, although transformation to high-grade carcinoma is occasionally seen. A pelvic S-LMP - low-grade serous carcinoma pathway has been proposed based on global gene
https://www.semanticscholar.org/paper/Benign-and-Low-Grade-Serous-Epithelial-Tumors-Rece-Longacre/41e3736af27e5685be5b4e479a4bdc98ac430580
Study Identifies Cells-of-origin of High-grade Serous Ovarian Cancer - OncoZine
Study identifies cell-of-origin in the development of many ovarian tumors, including including high grade serous ovarian carcinoma (HGSOC)
https://www.oncozine.com/study-identifies-cells-of-origin-of-high-grade-serous-ovarian-cancer/
High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma - pdf descargar
High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
http://libros.duhnnae.com/2017/jul/149888689342-High-expression-of-NQO1-is-associated-with-poor-prognosis-in-serous-ovarian-carcinoma.php
diagnosis of ovarian tumors - Humpath.com - Human pathology
See also ; ovarian tumors Appearance : ovarian epithelial tumors ovarian serous tumors benign ovarian serous tumors proliferating (...)
http://www.humpath.com/spip.php?article23131
JCI - An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in miceJCI - An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice
Mutations in the gene encoding the p110α subunit of PI3K (PIK3CA) that result in enhanced PI3K activity are frequently observed in human cancers. To better understand the role of mutant PIK3CA in the initiation or progression of tumorigenesis, we generated mice in which a PIK3CA mutation commonly detected in human cancers (the H1047R mutation) could be conditionally knocked into the endogenous Pik3ca locus. Activation of this mutation in the mouse ovary revealed that alone, Pik3caH1047R induced premalignant hyperplasia of the ovarian surface epithelium but no tumors. Concomitantly, we analyzed several human ovarian cancers and found PIK3CA mutations coexistent with KRAS and/or PTEN mutations, raising the possibility that a secondary defect in a co-regulator of PI3K activity may be required for mutant PIK3CA to promote transformation. Consistent with this notion, we found that Pik3caH1047R mutation plus Pten deletion in the mouse ovary led to the development of ovarian serous adenocarcinomas and ...
https://www.jci.org/articles/view/59309/figure/3
GRAF | Cancer Genetics Web
Complex focal chromosomal rearrangements in cancer genomes, also called firestorms, can be scored from DNA copy number data. The complex arm-wise aberration index (CAAI) is a score that captures DNA copy number alterations that appear as focal complex events in tumors, and has potential prognostic value in breast cancer. This study aimed to validate this DNA-based prognostic index in breast cancer and test for the first time its potential prognostic value in ovarian cancer. Copy number alteration (CNA) data from 1950 breast carcinomas (METABRIC cohort) and 508 high-grade serous ovarian carcinomas (TCGA dataset) were analyzed. Cases were classified as CAAI positive if at least one complex focal event was scored. Complex alterations were frequently localized on chromosome 8p (n = 159), 17q (n = 176) and 11q (n = 251). CAAI events on 11q were most frequent in estrogen receptor positive (ER+) cases and on 17q in estrogen receptor negative (ER-) cases. We found only a modest correlation between ...
http://www.cancerindex.org/geneweb/GRAF.htm
Low Grade Serous Ovarian Cancer - United StatesLow Grade Serous Ovarian Cancer - United States
Low grade serous ovarian cancer affects approximately 1 in 1000 women, many will be diagnosed in their 20s and 30s. With current medical treatments ...
https://cureourovariancancer.org/us/about/low-grade-serous-ovarian-cancer/
Prognostic significance of Notch 3 gene expression in ovarian serous carcinomaPrognostic significance of Notch 3 gene expression in ovarian serous carcinoma
The Notch signaling pathway is an important cell signaling system, which regulates cell differentiation, proliferation, and apoptosis, and is aberrantly activated in a wide range of cancer, including ovarian cancers. However, it remains unclear as to whether Notch signaling plays a role in the progr …
https://pubmed.ncbi.nlm.nih.gov/20624166/?dopt=Abstract
Ovarian cancer in lymph nodes. Chisturi de giardia în scaunul uman
Ovarian high-grade serous carcinoma is a type of malignancy that is rare among young adult women, being more frequent in postmenopausal wo-men. Cancer of the ovary, fallopian tube and peritoneum. Lymph Node Dissection for Ovarian Cancer gastric cancer research Leacuri detoxifiere ficat verruca foot sock, hpv e cancer de pulmao cancer femei simptome.
http://sprdiamantul.ro/ovarian-cancer-in-lymph-nodes.php
High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome | OncotargetHigh PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome | Oncotarget
https://doi.org/10.18632/oncotarget.21175 Véronique DHondt, Magalie Lacroix-Triki, Marta Jarlier, Florence Boissiere-Michot, Carole Puech, Peter Coopman, Dionyssios Katsaros, Gilles Freiss
https://www.oncotarget.com/article/21175/
Daniel J. Powell Jr. | Faculty | Center for Research on Reproduction and Womens Health | Perelman School of Medicine at the...
David Bowtell, Steffen Böhm, Ahmed Ahmed, Paul-Joseph Aspuria, Robert C Bast, Jr, Valerie Beral, Jonathan S Berek, Mike Birrer, Sarah Blagden, Michael A Bookman, James Brenton, Katherine B Chiappinelli, Filipe Correia Martins, George Coukos, Ronny Drapkin, Richard Edmondson, Christina Fotopoulou, Hani Gabra, Jérôme Galon, Charlie Gourley, Valerie Heong, David Huntsman, Marcin Iwanicki, Beth Karlan, Allyson Kaye, Ernst Lengyel, Douglas A Levine, Karen Lu, Iain McNeish, Usha Menon, Steve Narod, Brad H Nelson, Kenneth Nephew, Paul Pharoah, Daniel Powell, Pilar Ramos, Iris Romero, Clare Scott, Anil K Sood, Euan A Stronach, Frances Balkwill: Rethinking Ovarian Cancer II: A Roadmap for Reducing Mortality from High-grade Serous Ovarian Cancer. Nature Reviews Cancer 15(11): 668-79, Oct 2015 ...
http://www.med.upenn.edu/apps/faculty/index.php/g361/p8186734
UPENN Biomedical Graduate Studies | Daniel J. Powell Jr.
David Bowtell, Steffen Böhm, Ahmed Ahmed, Paul-Joseph Aspuria, Robert C Bast, Jr, Valerie Beral, Jonathan S Berek, Mike Birrer, Sarah Blagden, Michael A Bookman, James Brenton, Katherine B Chiappinelli, Filipe Correia Martins, George Coukos, Ronny Drapkin, Richard Edmondson, Christina Fotopoulou, Hani Gabra, Jérôme Galon, Charlie Gourley, Valerie Heong, David Huntsman, Marcin Iwanicki, Beth Karlan, Allyson Kaye, Ernst Lengyel, Douglas A Levine, Karen Lu, Iain McNeish, Usha Menon, Steve Narod, Brad H Nelson, Kenneth Nephew, Paul Pharoah, Daniel Powell, Pilar Ramos, Iris Romero, Clare Scott, Anil K Sood, Euan A Stronach, Frances Balkwill: Rethinking Ovarian Cancer II: A Roadmap for Reducing Mortality from High-grade Serous Ovarian Cancer. Nature Reviews Cancer 15(11): 668-79, Oct 2015 ...
http://www.med.upenn.edu/apps/faculty/index.php/g20000220/p8186734
Plus itPlus it
Purpose: In high-grade serous ovarian cancer (HGSOC), higher densities of both B cells and the CD8+ T cell infiltrate were associated with a better prognosis. However, the precise role of B cells in the anti-tumor response remains unknown. As peritoneal metastases are often responsible for relapse, our aim was to characterize the role of B cells in the anti-tumor immune response in HGSOC metastases. Experimental Design: Unmatched pre and post-chemotherapy HGSOC metastases were studied. B-cell localization was assessed by immunostaining. Their cytokines and chemokines were measured by multiplex assay and their phenotype was assessed by flow cytometry. Further in vitro and in vivo assays highlighted the role of B cells and plasma cell IgGs in the development of cytotoxic responses and dendritic cell activation. Results: B cells mainly infiltrated lymphoid structures in the stroma of HGSOC metastases. There was a strong B-cell memory response directed at a restricted repertoire of antigens and ...
http://clincancerres.aacrjournals.org/content/early/2016/06/25/1078-0432.CCR-16-0081
PNNL: BTRR Proteomics Resource - PublicationsPNNL: BTRR Proteomics Resource - Publications
PMID: 26867183, PMCID: PMC5271177. Integrated proteogenomic characterization of human high-grade serous ovarian cancer, H. Zhang, T. Liu, Z. Zhang, S. H. Payne, B. Zhang, J. E. McDermott, J. Y. Zhou, V. A. Petyuk. L. Chen, D. Ray, S. Sun, F. Yang, L. Chen, J. Wang, P. Shah, S. W. Cha, P. Aiyetan, S. Woo, Y. Tian, M. A. Gritsenko, T. R. Clauss, C. Choi, M. E. Monroe, S. Thomas, S. Nie, C. Wu, R. J. Moore, K. H. Yu, D. L. Tabb, D. Fenyo, V. Bafna, Y. Wang, H. Rodriguez, E. S. Boja, T. Hiltke, R. C. Rivers, L. Sokoll, H. Zhu, IeM. Shih, L. Cope, A. Pandey, B. Zhang, M. P. Snyder, D. A. Levine, R. D. Smith, D. W. Chan, K. D. Rodland, and CPTAC Investigators, Cell 166 (3): 755-765 (2016 ...
https://panomics.pnnl.gov/publications/2016pubs.stm
KRAS Mutation in Serous Borderline Tumor of the Testis: Report of a Case and Review of the LiteratureKRAS Mutation in Serous Borderline Tumor of the Testis: Report of a Case and Review of the Literature
Ovarian-like epithelial tumors of the testis, including serous borderline tumors, are rare entities. We report the case of a 60-year-old man with a left intratesticular mass who had a radical orchidectomy. Histologically, the tumor was identical to the ovarian counterpart showing a well-delineated cystic lesion characterized by intraluminal papillae. The papillae are lined by atypical cuboidal or ciliated cells and are associated with psammoma bodies. The tumor cells express cytokeratin 7 (CK7), cytokeratin 5-6 (CK5-6), cancer antigen 125 (CA125), estrogen (ER), progesterone (PR), Wilm’s tumor gene (WT1), paired box gene 8 (PAX8), Ber-EP4, and epithelial membrane antigen (EMA). The diagnosis of a serous borderline tumor of the testis was proposed. Mutation testing using next-generation sequencing showed a Q61K KRAS gene mutation. To the best of our knowledge, this is the second case report of a serous borderline tumor of the testis with a Q61K KRAS gene mutation.
https://www.hindawi.com/journals/criu/2020/5419707/
Low-grade serous carcinoma (mullerian/ovarian type) of the paratestis presenting as diffuse metastatic disease of unknown...
TY - JOUR. T1 - Low-grade serous carcinoma (mullerian/ovarian type) of the paratestis presenting as diffuse metastatic disease of unknown origin. T2 - Case report of an uncommon tumor with an unusual presentation. AU - Filatenkov, Alexander. AU - Strickland, Amanda. AU - Karpowicz, Matthew. AU - Francis, Franto. N1 - Publisher Copyright: © 2017 The Authors Copyright: Copyright 2017 Elsevier B.V., All rights reserved.. PY - 2018/3. Y1 - 2018/3. N2 - Low-grade (papillary) serous carcinoma of ovarian type is rare in males and histologically identical to low-grade serous carcinomas in female patients. We present a case of paratesticular low-grade serous carcinoma in a 42 year old male, with the highly unusual initial presentation as diffuse metastatic disease in the abdomen. Imaging revealed a cystic lesion of the right testis/hemiscrotum. Biopsy of the abdominal metastasis and subsequent right orchiectomy specimen showed invasive papillary serous carcinoma, low grade, with prominent psammomatous ...
https://utsouthwestern.pure.elsevier.com/en/publications/low-grade-serous-carcinoma-mullerianovarian-type-of-the-paratesti
Outcome after combined modality treatment for uterine papillary serous carcinoma: A study by the Rare Cancer Network (RCN)<...
TY - JOUR. T1 - Outcome after combined modality treatment for uterine papillary serous carcinoma. T2 - A study by the Rare Cancer Network (RCN). AU - Goldberg, Hadassah. AU - Miller, Robert C.. AU - Abdah-Bortnyak, Roxolyana. AU - Steiner, Mariana. AU - Yildiz, Ferah. AU - Meirovitz, Amichay. AU - Villà, Salvador. AU - Poortmans, Philip M.P.. AU - Azria, David. AU - Zidan, Jamal. AU - Ozsahin, Mahmut. AU - Abacioglu, Ufuk. AU - Gold, Douglas G.. AU - Amit, Amnon. AU - Lavie, Ofer. AU - Atahan, I. Lale. AU - Kuten, Abraham. PY - 2008/2/1. Y1 - 2008/2/1. N2 - Objectives: Uterine papillary serous carcinoma (UPSC) is a rare subtype of endometrial carcinoma, characterized by a poor outcome. We sought to better analyze the effect of surgery and adjuvant therapies on this disease. Methods: A retrospective analysis was performed on the records of 138 women diagnosed with UPSC between 1986 and 2003 in the framework of the Rare Cancer Network. Results: Median age at diagnosis was 67 years. Pure UPSC was ...
https://mayoclinic.pure.elsevier.com/en/publications/outcome-after-combined-modality-treatment-for-uterine-papillary-s
Ovarian serous cystadenofibromas associated with a low-grade serous carcinoma of the peritoneum<...
TY - JOUR. T1 - Ovarian serous cystadenofibromas associated with a low-grade serous carcinoma of the peritoneum. AU - Hinson, Stacy A.. AU - Silva, Elvio G.. AU - Pinto, K.. PY - 2013/6/1. Y1 - 2013/6/1. N2 - Ovarian serous cystadenofibromas are benign neoplasms that sometimes have focal areas of borderline serous tumor and rarely have been associated with epithelial proliferations in the peritoneum, resembling implants. We are reporting 2 cases of ovarian serous cystadenofibromas with serous peritoneal lesions of higher grade than the ovarian tumor: 1 case had a serous carcinoma and another 1 a serous borderline tumor.. AB - Ovarian serous cystadenofibromas are benign neoplasms that sometimes have focal areas of borderline serous tumor and rarely have been associated with epithelial proliferations in the peritoneum, resembling implants. We are reporting 2 cases of ovarian serous cystadenofibromas with serous peritoneal lesions of higher grade than the ovarian tumor: 1 case had a serous ...
https://utsouthwestern.pure.elsevier.com/en/publications/ovarian-serous-cystadenofibromas-associated-with-a-low-grade-sero
Cervical Serous Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical TrialsCervical Serous Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials
MalaCards based summary : Cervical Serous Adenocarcinoma is related to thymus clear cell carcinoma and adult type testicular granulosa cell tumor. An important gene associated with Cervical Serous Adenocarcinoma is MLANA (Melan-A), and among its related pathways/superpathways are NF-kappaB Signaling and Primary Focal Segmental Glomerulosclerosis FSGS. Related phenotype is no phenotypic analysis ...
https://www.malacards.org/card/cervical_serous_adenocarcinoma?search=MLANA
A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma - Full Text...A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma - Full Text...
Uterine papillary serous carcinoma (UPSC) is an uncommon, but aggressive variant of endometrial carcinoma that has a high recurrence rate and poor response to therapy. It has a propensity to metastasize throughout the abdomen, similar to serous carcinoma of the ovary. In fact, many patients with disease apparently confined to the uterus have microscopic intra-abdominal spread at the time of diagnosis. Recurrences are common both in the pelvis as well as in the upper abdomen.. After staging and debulking of gross disease, adjuvant radiation therapy is recommended to treat patients with endometrial carcinoma at high risk for recurrent disease. High-risk features include histologic cell type, grade, depth of myometrial invasion, cervical extension, lymph-vascular invasion, adnexal involvement, intraperitoneal spread, positive peritoneal cytology, and positive lymph nodes. Pelvic radiation can limit local recurrences to less than 6.5%. However, approximately 25-30% of patients with high-risk ...
https://clinicaltrials.gov/ct2/show/NCT00231868?cond=%22Adenocarcinoma+of+the+appendix%22&rank=20
Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma<...
TY - JOUR. T1 - Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma. AU - Ayeni, Tina A.. AU - Bakkum-Gamez, Jamie N. AU - Mariani, Andrea. AU - McGree, Michaela E.. AU - Weaver, Amy L.. AU - Alhilli, Mariam M.. AU - Martin, Janice R.. AU - Keeney, Gary. AU - Dowdy, Sean Christopher. AU - Podratz, Karl C.. PY - 2013/1. Y1 - 2013/1. N2 - Objective: Abdominal peritoneal implants are characteristic of uterine serous carcinoma (USC). The presumed mechanism of dissemination is retrograde transit via the fallopian tube. We assessed the impact of tubal ligation (TL) on the metastatic profile and survival of USC patients. Methods: Patient risk factors, process-of-care variables, and disease-specific parameters were annotated. Categorical variables were compared using the χ2 test. Overall survival (OS) was estimated via the Kaplan-Meier method. Results: Among 211 USC patients, fallopian tube status was documented in 142 patients; 35 had a history of TL ...
https://mayoclinic.pure.elsevier.com/en/publications/impact-of-tubal-ligation-on-routes-of-dissemination-and-overall-s
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomesStage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
Objectives: To determine recurrence patterns and survival outcomes of stage II uterine papillary serous carcinoma (UPSC) patients treated by various modalities with an emphasis on carboplatin/paclitaxel-based chemotherapy (CT) +/- radiotherapy (RT). Methods: A retrospective, multi-institution study of women with stage II UPSC diagnosed from 1992 to 2006 was performed. All patients underwent comprehensive surgical staging. Treatment included observation (OBS), RT (vaginal brachytherapy, whole pelvic and/or whole abdominal therapy), or ≥ 3 cycles carboplatin/paclitaxel alone or with RT. Recurrence and survival outcomes were determined. Results: We identified 55 subjects: 10 treated with OBS, 26 with RT alone and 19 with CT +/- RT. After a median follow-up of 33 mos (range, 10-119), 20 recurrences (36%) were observed. There was an overall difference in recurrence based upon treatment (p = .013). Specifically, all CT +/- RT treated patients had a lower risk of recurrence (11%) compared to patients ...
http://scholars.uab.edu/display/pub2150918
Mass spectrometry-based peptidome profiling of human serous ovarian cancer tissues | Bioinformatics Solutions Inc.Mass spectrometry-based peptidome profiling of human serous ovarian cancer tissues | Bioinformatics Solutions Inc.
Xu, J., et al. Mass spectrometry-based peptidome profiling of human serous ovarian cancer tissues. The International Journal of Biochemistry & Cell Biology. S1357-2725(18)30258-9. 10/12/2018.. We identified 634 differentially expressed peptides, 508 of these peptides were highly abundant in serous ovarian cancer tissues, a result consistent with higher protease activity in ovarian cancer patients. The difference in preferred cleavage sites between the serous ovarian cancer tissues and normal ovarian epithelium indicates the characteristic peptidome of ovarian cancer and the nature of cancer-associated protease activity. Interestingly, KEGG pathway analysis of the peptide precursors indicated that the differentially regulated pathways in ovarian cancer are highly consistent with the pathways discovered in other cancers. Besides, we found that a proportion of the differentially expressed peptides are similar to the known immune-regulatory peptides and anti-bacterial peptides. Then we further ...
https://www.bioinfor.com/mass-spectrometry-based-peptidome-profiling-human-serous-ovarian-cancer-tissues/
Uterine papillary serous carcinoma: A rare type of endometrial carcinoma with worse outcomes-IJOGR-IP Innovative Publication...
Uterine papillary serous carcinoma: A rare type of endometrial carcinoma with worse outcomes-IJOGR-Print ISSN No:-2394-2746 Online ISSN No:-2394-2754Article DOI No:-10.18231/2394-2754.2019.0022,Indian Journal of Obstetrics and Gynecology Research-IP Innovative Publication Pvt Limited, Medical Journals Publication, Op
https://www.innovativepublication.com/journals/IJOGR/article-details/8633/volume/243/issue/673
Precursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular CharacteristicsPrecursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular Characteristics
Journal of Oncology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to breast cancer, lung cancer, gastrointestinal cancer, skin cancer, head and neck cancer, paediatric oncology, neurooncology as well as genitourinary cancer. The journal provides a multidisciplinary forum for translational and clinical oncology research in the areas of molecular pathology, genomics, diagnosis and therapy, with a specific focus on molecular targeted agents and novel immune therapies.
https://www.hindawi.com/journals/jo/2010/126295/abs/
Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct...Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct...
Researchers used Caris Molecular Intelligence® to evaluate 240 uterine papillary serous carcinoma (UPSC) and 1,587 epithelial ovarian serous carcinoma (EOC-S) samples, and to compare the molecular profiles of the two cancer subtypes.. The tumor suppressor gene TP53 was the most commonly mutated gene in both UPSC and EOC-S (76% vs. 69%) samples. UPSCs were more likely than EOC-S samples to harbor mutations in the oncogenes PIK3CA (29% vs. 2%), FBXW7 (12% vs. 1%), KRAS (9% vs. 5%), the tumor suppressor protein PTEN (7% vs. 1%), and CTNNB1 (2% vs. 0%).. Whereas uterine papillary serous carcinoma appears to have a distinct mutation profile, indicating higher activity of the PI3K/PTEN/mTOR pathway, we saw no differences between uterine papillary and ovarian serous carcinomas in alteration of the homologous recombination pathway, remarked principal investigator Robert DeBernardo, MD, Gynecologic Oncologist and Director of Minimally Invasive Surgery at the Cleveland Clinic Ob/Gyn & Womens Health ...
https://www.carislifesciences.com/news/caris-molecular-intelligence-facilitates-comparison-of-biomarker-profiles-to-inform-targeted-treatment-strategies-in-distinct-gynecological-cancers/
CAISMOV24, a new human low-grade serous ovarian carcinoma cell line | BMC Cancer | Full TextCAISMOV24, a new human low-grade serous ovarian carcinoma cell line | BMC Cancer | Full Text
In this study a new low-grade serous ovarian carcinoma cell line, named as CAISMOV24, was characterized in terms of its in vitro cell growth, production of soluble biomarkers and expression of cell surface molecules. Additionally, CAISMOV24 was molecularly characterized and compared to its primary malignant cells for genomic alterations. In vitro models of well-characterized low-grade serous ovarian cell lines are currently limited in the literature. CAISMOV24 resulted from the in vitro spontaneous immortalization of primary malignant cells from ascites that was associated with a low-grade serous ovarian carcinoma. Although malignant cells of ovarian neoplasia from either tumor tissue or ascites can be cultivated in vitro for a limited period, only a minority of the primary cell cultures may become cell lines [14]. Spontaneous immortalization of primary cultures of malignant cells is an event occurring at a very low frequency. As an example, ODonnell et al. [11] reported the occurrence of only ...
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3716-4
Is invasive micropapillary serous carcinoma a low-grade carcinoma?<...
TY - JOUR. T1 - Is invasive micropapillary serous carcinoma a low-grade carcinoma?. AU - Ohishi, Yoshihiro. AU - Imamura, Hiroko. AU - Aman, Murasaki. AU - Shida, Kaai. AU - Kaku, Tsunehisa. AU - Kato, Kiyoko. AU - Oda, Yoshinao. PY - 2016/1/1. Y1 - 2016/1/1. N2 - Invasive micropapillary serous carcinoma has been proposed as a synonym for low-grade serous carcinoma by some expert pathologists. In contrast, Singer and colleagues reported that some serous carcinomas with conspicuous invasive micropapillary pattern (SC-IMPs) can show high-grade nuclear atypia. However, the molecular features of such tumors have not been well documented. The aim of this study was to demonstrate and emphasize the fact that high-grade serous carcinoma confirmed by immunohistochemistry and molecular analysis can show conspicuous invasive micropapillary pattern. We selected 24 SC-IMPs and investigated: (1) their morphologic features; (2) the immunostaining pattern of p53 protein; and (3) KRAS/BRAF/TP53 gene ...
https://kyushu-u.pure.elsevier.com/en/publications/is-invasive-micropapillary-serous-carcinoma-a-low-grade-carcinoma
MRI appearance of ovarian serous borderline tumors of the micropapillary type compared to that of typical ovarian serous...MRI appearance of ovarian serous borderline tumors of the micropapillary type compared to that of typical ovarian serous...
Serous borderline tumor (SBT) of the micropapillary type (SBT-MP) became one of the major pathological SBT diagnoses in addition to typical SBT, and was also defined as
https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-018-0379-y
uterine serous carcinoma survival rates
Weve invested more than $4.9 billion in cancer research since 1946, all to find more - and better - treatments, uncover factors that may cause cancer, and improve cancer patients quality of life. Instead, it groups cancers into localized, regional, and distant stages: (Based on people diagnosed with endometrial cancer between 2009 and 2015. ), *SEER= Surveillance, Epidemiology, and End Results, The American Cancer Society medical and editorial content team. Due to this notion, every patient and even non-patient will not like to reach this kind of stage. For patients with FIGO Stage IA, IB, and IC UPSC who underwent complete surgical staging, the 5-year actuarial DFS by depth of myometrial invasion was 100, 71, and 40%, respectively (p = 0.006). For example, endometrioid carcinomas have a more favourable prognosis than serous adenocarcinomas. Stage: 3 Survival Rate: 30 percent. We couldnt do what we do without our volunteers and donors. Making Strides Against Breast Cancer Walks, Common ...
https://www.whyplayit.se/pudbgks/eaf5de-uterine-serous-carcinoma-survival-rates
Most recent papers with the keyword Uterine serous cancer | Read by QxMDMost recent papers with the keyword Uterine serous cancer | Read by QxMD
Epithelial ovarian cancer is a leading cause of death in gynecological cancers. While several systematic studies have revealed the mutation landscape of serous epithelial ovarian cancer, other non-serous subtypes of the disease have not been explored as extensively. Here we conduct exome sequencing of nine non-serous epithelial ovarian tumors (six endometrioid and three mucinous) and their corresponding normal DNA as well as a tumor-only granulosa cell sample. We integrated the exome data with targeted gene sequencing for 1,321 genes selected for their involvement in cancer from additional 28 non-serous ovarian tumors and compared our results to TCGA ovarian serous cystadenocarcinoma and uterine corpus endometrial carcinomas ...
https://www.readbyqxmd.com/keyword/16962
Uterine Papillary Serous Carcinoma (UPSC): any others here??? | Cancer Survivors NetworkUterine Papillary Serous Carcinoma (UPSC): any others here??? | Cancer Survivors Network
I guess my hamster days steroid high is over, because I slept 10 hours last night and woke up with something similar to what Marge described, a sort of fogginess. Its not bad, but I feel like if I crawled back under the covers, I just might go back to sleep again. (Not doing that!) I agree that we are all doing so much better than any of us probably dared to hope. There are surely some rough days ahead, but one day at a time is the way to go, and making the most of each good day. I wonder if we will continue to come here after our treatments are over??? I see 20-year survivors posting here on other boards, wanting to be here as a resource to those that come after them with their same cancers. Id like to think well be like that, with this thread always flagged for email alerts, ready to jump back in when those newly diagnosed with UPSC using the SEARCH box, find this thread. Even if any of us decide to close the door on this chapter of our life and never look back, think how great it will ...
https://csn.cancer.org/node/163120?page=1
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis...Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis...
We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in
https://www.garvan.org.au/research/collaborative-programs/circa/publications/14723
5 Easy Facts About best provestra review Described5 Easy Facts About best provestra review Described
Zanotti The Cleveland Clinic Foundation Uterine papillary serous carcinoma (UPSC) is undoubtedly an intense malignancy which has a histologic visual appeal and pattern of spread that resembles that of papillary serous adenocarcinoma with the ovary. The current conventional therapy for Superior ovarian most cancers, cisplatin or carboplatin moreover paclitaxel, results in high aim response premiums for that tumor. This program has Up to now not been evaluated in i thought about this UPSC. Approaches: 20-four sufferers with UPSC treated with platinum-based mostly chemotherapy and paclitaxel were being retrospectively evaluated. Eighteen clients acquired these agents within the adjuvant placing (n = 9) or for sickness persistent just after initial surgical management (n = nine). Eleven patients gained one or more classes of this drug blend for recurrent ailment, 5 of whom experienced prior publicity while in the First setting ...
http://amazonsupplements29517.timeblog.net/3342906/5-easy-facts-about-best-provestra-review-described
Plus itPlus it
Mutations in BRCA1 or BRCA2 (BRCA) are common in patients with high-grade serous ovarian carcinomas, and, when the wild-type allele is lost, BRCA mutations can impair DNA-damage repair by homologous recombination, leading to deletion or duplication of chromosomal regions, which is termed genomic loss of heterozygosity (LOH). Homologous recombination-deficient tumors are sensitive to PARP inhibitors such as rucaparib, but although homologous recombination deficiencies can also occur in ovarian tumors without BRCA mutations, molecular predictors of rucaparib sensitivity in BRCA wild-type tumors have not been identified. Swisher, Lin, and colleagues hypothesized that genomic LOH might predict homologous recombination deficiency and rucaparib sensitivity and enrolled 206 patients in an open-label phase II trial of rucaparib in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma. In total, 192 patients could be classified into subgroups: 40 had BRCA mutations, 82 were BRCA ...
http://cancerdiscovery.aacrjournals.org/content/7/1/OF8
Stefanie Ueda, MD | Obstetrics, Gynecology & Reproductive SciencesStefanie Ueda, MD | Obstetrics, Gynecology & Reproductive Sciences
Ueda SM, Yap, KL, Davidson, B et al. Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J Oncology 2010;2010:285191.. Krill LS, Ueda SM, Gerardi M, Bristow RE. Analysis of postoperative complications associated with the use of anti-adhesion sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier after cytoreductive surgery for ovarian, fallopian tube and peritoneal cancers. Article in press for Gynecol Oncol. 2011 Feb; 120(2):220-3. Skaznik-Wikiel ME, Ueda SM, Frasure HE, Rose PG, Fleury A, Grumbine FC, Nickles-Fader A. Abnormal cervical cytology in the diagnosis of uterine papillary serous carcinoma: earlier detection of a poor prognostic cancer subtype? Acta Cytol 2001;55(3):255-60.. Bristow RE, Ueda S, Gerardi MA, Ajiboye OB, Ibeanu OA. Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecol Oncol 2011;122(2):319-23.. Giuntoli RL, Gerardi ...
http://obgyn.ucsf.edu/gynecologic-oncology/stefanie-ueda-md
Plus itPlus it
Cancer cell lines have been, and will continue to be, important tools in oncology research, but there are major limitations in the fidelity of existing cell lines as a model of human cancers. Therefore, the aim of our study was to generate and characterize patient-specific cell lines from solid tumors that more faithfully recapitulate the primary tumor genetic and morphologic characteristics.. We performed cell line derivation on a primary human breast adenocarcinoma (ER+/PR+/HER2-), a lung adenocarcinoma, a high-grade serous ovarian carcinoma, and an endometrioid ovarian carcinoma procured from a commercial tissue bank. Portions were snap-frozen for molecular analysis, and the remainder was minced and processed for cell culture. Cells were cultured and the resulting monolayer was stained by immunocytochemistry with a pan-keratin antibody for the presence of epithelial cells. Any contaminating fibroblasts were removed. We extracted DNA from the resulting breast and lung cancer cell lines at low, ...
http://clincancerres.aacrjournals.org/content/22/1_Supplement/33
Michele Cote - Oncology - Wayne State UniversityMichele Cote - Oncology - Wayne State University
4. Mills AM, Peres LC, Meiss A, Ring KL, Modesitt SC, Abbott SE, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy ML, Cote ML, Funkhouser E, Moorman PG, Peters ES, Schwartz AG, Terry PD, Wallace K, Schildkraut JM. Targetable immune regulatory molecule expression in high-grade serous ovarian carcinomas in African American women: A study of PD-L1 and IDO in 112 cases from the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol. 2018 Feb 26 [Epub ahead of print]. IF: 1.5 Role: Subject recruitment, data analysis, manuscript preparation. 5. Holowatyj AN*, Cote ML, Ruterbusch JJ, Ghanem K, Schwartz AG, Vigneau FD, Gorski DH, Purrington KS. Racial differences in 21-Gene recurrence scores among patients with hormone receptor-positive, node-negative breast cancer. J Clin Oncol. 2018 Mar 1; 36(7):652-658. IF: 24.0. 6. Peres LC, Risch H, Terry KL, Webb PM, Goodman MT, Wu AH, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy ML, Cote ML, Funkhouser E, Moorman PG, Peters ES, Schwartz AG, ...
https://oncology.med.wayne.edu/profile/ag9147
Definition and Algorithm | Ovarian Cancer Prevention, Detection and TreatmentDefinition and Algorithm | Ovarian Cancer Prevention, Detection and Treatment
Faculty contributors to the definition and algorithm:. Drs. R. Vang, R.J. Kurman, K. Visvanathan, P. Shaw, R. Soslow, V. Parkash, and I. Shih. The intention of the information provided in this web site is at present for educational and research purposes only. The biological and clinical significance of STIC and STIL is a work in progress and their impact to clinical management has still to be defined. The investigators involved in this study and all the web pages in ovariancancerprevention.org do not recommend the use of this pathological and immunostaining classification for clinical practice at the present time. Ovarian high-grade serous carcinoma (HGSC) is the most lethal gynecologic malignancy and is characterized by frequent TP53 mutations and a high level of chromosomal instability, which is reflected by widespread DNA copy number changes compared to other types of epithelial ovarian carcinomas. Unlike cancers arising in the colon, breast, cervix, endometrium, prostate, and pancreas, for ...
http://www.ovariancancerprevention.org/?page_id=191
Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers<...Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers<...
TY - JOUR. T1 - Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers. AU - Liu, Guoyan. AU - Yang, Da. AU - Rupaimoole, Rajesha. AU - Pecot, Chad V.. AU - Sun, Yan. AU - Mangala, Lingegowda S.. AU - Li, Xia. AU - Ji, Ping. AU - Cogdell, David. AU - Hu, Limei. AU - Wang, Yingmei. AU - Rodriguez-Aguayo, Cristian. AU - Lopez-Berestein, Gabriel. AU - Shmulevich, Ilya. AU - De Cecco, Loris. AU - Chen, Kexin. AU - Mezzanzanica, Delia. AU - Xue, Fengxia. AU - Sood, Anil K.. AU - Zhang, Wei. N1 - Publisher Copyright: © 2015 The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: [email protected] PY - 2015/7/1. Y1 - 2015/7/1. N2 - Background: Chemoresistance is a major challenge in cancer treatment. miR-506 is a potent inhibitor of the epithelial-to-mesenchymal transition (EMT), which is also associated with chemoresistance. We characterized the role of miR-506 in chemotherapy ...
https://researchexperts.utmb.edu/en/publications/augmentation-of-response-to-chemotherapy-by-microrna-506-through-
Are Epithelial Ovarian Cancers of the Mesenchymal Subtype Actually Intraperitoneal Metastases to the Ovary?Are Epithelial Ovarian Cancers of the Mesenchymal Subtype Actually Intraperitoneal Metastases to the Ovary?
Author(s): Hu, Ye; Taylor-Harding, Barbie; Raz, Yael; Haro, Marcela; Recouvreux, Maria Sol; Taylan, Enes; Lester, Jenny; Millstein, Joshua; Walts, Ann E; Karlan, Beth Y; Orsulic, Sandra | Abstract: Primary ovarian high-grade serous carcinoma (HGSC) has been classified into 4 molecular subtypes: Immunoreactive, Proliferative, Differentiated, and Mesenchymal (Mes), of which the Mes subtype (Mes-HGSC) is associated with the worst clinical outcomes. We propose that Mes-HGSC comprise clusters of cancer and associated stromal cells that detached from tumors in the upper abdomen/omentum and disseminated in the peritoneal cavity, including to the ovary. Using comparative analyses of multiple transcriptomic data sets, we provide the following evidence that the phenotype of Mes-HGSC matches the phenotype of tumors in the upper abdomen/omentum: (1) irrespective of the primary ovarian HGSC molecular subtype, matched upper abdominal/omental metastases were typically of the Mes subtype, (2) the Mes subtype was
https://escholarship.org/uc/item/9kr1662h
Papillary serous ovarian carcinoma | Case StudiesPapillary serous ovarian carcinoma | Case Studies
of the uterus, adenexae, onsectonomy and appendectomy for papillary serous carcinoma of the ovary . After 6 chemotherapy cycles tumor recurrence .... ...
http://www.doctorsmedicalopinion.com/search/node/Papillary%20serous%20%20ovarian%20carcinoma
A Comparison of WT1, PTEN and the AKT Pathway in Ovarian Serous Carcinoma vs. Colorectal Adenocarcinoma - Research Database,...
Bouchalova, P., Nenutil, R., Muller, P., Hrstka, R., Appleyard, M. V., Murray, K., Jordan, L. B., Purdie, C. A., Quinlan, P., Thompson, A. M., Vojtesek, B. & Coates, P. J. Jul 2014 In : Journal of Pathology. 233, 3, p. 238-246 9 p.. Research output: Contribution to journal › Article ...
http://discovery.dundee.ac.uk/portal/en/research/a-comparison-of-wt1-pten-and-the-akt-pathway-in-ovarian-serous-carcinoma-vs-colorectal-adenocarcinoma
Plus itPlus it
Patients with ovarian high-grade serous carcinoma (HGSC) initially respond to treatment with the chemotherapeutic agents carboplatin and paclitaxel, but frequently experience tumor relapse. However, the mechanisms underlying the development of resistance to these drugs remain poorly understood. Yu and colleagues found that the levels of spleen tyrosine kinase (SYK) and phosphorylated SYK were increased in recurrent ovarian tumors isolated from patients previously treated with carboplatin and paclitaxel compared with matched primary untreated tumors. In addition, SYK expression and activation were upregulated in paclitaxel-resistant ovarian cancer cell lines and positively correlated with paclitaxel response in vitro, suggesting that SYK overexpression may confer chemoresistance. SYK inactivation via knockdown or pharmacologic inhibition with the active metabolite of fostamatinib, R406, impaired the growth of ovarian cancer cells and synergistically enhanced the sensitivity of ...
http://cancerdiscovery.aacrjournals.org/content/5/8/793.2
The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic reviewThe role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review
The present review showed that IRT alone may be an adequate RT technique in women with stage I USC, who underwent appropriate surgical staging and received adjuvant chemotherapy.. Uterine serous carcinoma patients have a high-risk to develop local and distant relapse [28], therefore it is essential to ensure an adequate treatment even if patients with an early stage disease. While prospective studies have demonstrated that the delivery of chemotherapy in combination with external beam radiation in an advanced stage disease may increase survival benefit and decreases local recurrences [29,30,31,32,33], the role of radiation in early stage USC has been more difficult to demonstrate.. Owing to high-rate of distant recurrences, many studies recommended a more systemic approach to therapy for USC [34]. Treatment of women with uterine-confined USC with adjuvant chemotherapy is controversial due to lack of prospective randomized trials. However, in patients with stage I/II disease who were treated with ...
https://www.termedia.pl/The-role-of-vaginal-brachytherapy-in-stage-I-endometrial-serous-cancer-a-systematic-review,54,39754,1,1.html
JCDR - Citation Manager Cite this Article Clinico Pathological Analysis of Uterine Serous Carcinoma in a Cancer Centre from...JCDR - Citation Manager Cite this Article Clinico Pathological Analysis of Uterine Serous Carcinoma in a Cancer Centre from...
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.
https://jcdr.net/citation_mgr.asp?issn=&year=2018&month=May&volume=12&issue=5&page=EC22&id=11539
Flaviopierleoni » GuestBook
Brain Development The shaky pattern continues to knowledgeable everywhere early, and the developing in ceo circumference is indicative of wit growth. Shifting Responsibilities From Hospital-Based to Community-Based Nursing Care Over the sometime century changes in vigorousness attention, such as uncomfortable salubrity care funding, shorter asylum stays, and sell for containment, include led to a make it in responsibilities of care payment children from the infirmary to homes and communities. Chemic toxins are each approximately you in cleansing supplies, pesticides, herbicides, and matter additives generic 30 gm himcolin with mastercard natural erectile dysfunction treatment remedies. Patterns of p53 mutations partition ovarian serous borderline tumors and low- and high-grade carcinomas and provide keep proper for a new prototype of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Non-critical stimulation coupled effects (viscerosensory symptoms, cough, ...
http://www.flaviopierleoni.com/guestbook/?from=36640&select=3665
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. - PubMed - NCBIIntraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. - PubMed - NCBI
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
https://www.ncbi.nlm.nih.gov/pubmed/17255760?dopt=Abstract
Reseach reveals genomic similarities between breast cancer, ovarian cancersReseach reveals genomic similarities between breast cancer, ovarian cancers
One subtype of breast cancer shares many genetic features with high-grade serous ovarian cancer, a cancer that is very difficult to treat, according to researchers supported by the National Institutes of Health. The findings suggest that the two cancers are of similar molecular origin, which may facilitate the comparison of therapeutic data for subtypes of breast and ovarian cancers.
https://medicalxpress.com/news/2012-09-reseach-reveals-genomic-similarities-breast.html
CiNii Articles - Yoshinaga Kousuke
Decreased Expression of 14-3-3,i,σ,/i, Is Predictive of Poor Prognosis for Patients with Human Uterine Papillary Serous Carcinoma （2013 ...
https://ci.nii.ac.jp/author?q=Yoshinaga+Kousuke
Ovarian Cancer Development and Metastasis - ScienceOpenOvarian Cancer Development and Metastasis - ScienceOpen
The biology of ovarian carcinoma differs from that of hematogenously metastasizing tumors because ovarian cancer cells primarily disseminate within the peritoneal cavity and are only superficially invasive. However, since the rapidly proliferating tumors compress visceral organs and are only temporarily chemosensitive, ovarian carcinoma is a deadly disease, with a cure rate of only 30%. There are a number of genetic and epigenetic changes that lead to ovarian carcinoma cell transformation. Ovarian carcinoma could originate from any of three potential sites: the surfaces of the ovary, the fallopian tube, or the mesothelium-lined peritoneal cavity. Ovarian cacinoma tumorigenesis then either progresses along a stepwise mutation process from a slow growing borderline tumor to a well-differentiated carcinoma (type I) or involves a genetically unstable high-grade serous carcinoma that metastasizes rapidly (type II). During initial tumorigenesis, ovarian carcinoma cells undergo an ...
https://www.scienceopen.com/document?vid=fb3207b4-62e9-4cd7-a546-6c03353f5228
A Study Combining the Peposertib (M3814) Pill with Standard Chemotherapy in Patients with Ovarian Cancer with an Expansion in...A Study Combining the Peposertib (M3814) Pill with Standard Chemotherapy in Patients with Ovarian Cancer with an Expansion in...
A Study Combining the Peposertib (M3814) Pill with Standard Chemotherapy in Patients with Ovarian Cancer with an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer - NCT04092270
https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2019-06123&r=1
Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer...Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer...
Siddhartha P. Kar, Jonathan P. Tyrer, Qiyuan Li, Kate Lawrenson, Katja K.H. Aben, Hoda Anton-Culver, Natalia Antonenkova, Georgia Chenevix-Trench, ; on behalf of the Australian Cancer Study, ; and on behalf of the Australian Ovarian Cancer Study Group, Helen Baker, Elisa V. Bandera, Yukie T. Bean, Matthias W. Beckmann, Andrew Berchuck, Maria Bisogna, Line Bjørge, Natalia Bogdanova, Louise Brinton, Angela Brooks-Wilson, Ralf Butzow, Ian Campbell, Karen Carty, Jenny Chang-Claude, Yian Ann Chen, Zhihua Chen, Linda S. Cook, Daniel Cramer, Julie M. Cunningham, Cezary Cybulski, Agnieszka Dansonka-Mieszkowska, Joe Dennis, Ed Dicks, Jennifer A. Doherty, Thilo Dörk, Andreas du Bois, Matthias Dürst, Diana Eccles, Douglas F. Easton, Robert P. Edwards, Arif B. Ekici, Peter A. Fasching, Brooke L. Fridley, Yu-Tang Gao, Aleksandra Gentry-Maharaj, Graham G. Giles, Rosalind Glasspool, Ellen L. Goode, Marc T. Goodman, Jacek Grownwald, Patricia Harrington, Philipp Harter, Alexander Hein, Florian Heitz, Michelle ...
http://cebp.aacrjournals.org/content/24/10/1574.article-info
My Faux EyebrowsMy Faux Eyebrows
My name is Shirley Pattan, I live in Jacksonville, Florida with my spouse, two (of five!) kids, and three fur babies. I was diagnosed at 40 July 2017 with stage 3c high grade serous ovarian cancer, which prompted testing for the BRCA mutation.
https://www.humorbeatscancer.com/post/my-faux-eyebrows
Tumor apelin immunoreactivity is correlated with body mass index in ovarian high grade serous carcinoma. | AVESİSTumor apelin immunoreactivity is correlated with body mass index in ovarian high grade serous carcinoma. | AVESİS
Atıf İçin Kopyala Unal I., Khiavi I., Tasar G., Goksuluk D. , Boyraz G., Ozgul N., ...Daha Fazla Biotechnic & histochemistry : official publication of the Biological Stain Commission, ss.1-10, 2019 (SCI İndekslerine Giren Dergi) ...
https://avesis.hacettepe.edu.tr/yayin/b08214ae-a018-4735-8a7c-b99738d61918/tumor-apelin-immunoreactivity-is-correlated-with-body-mass-index-in-ovarian-high-grade-serous-carcinoma
Serous cystadenocarcinomaSerous cystadenocarcinoma
... is a type of tumor in the cystadenocarcinoma grouping. Most commonly, the primary site of serous ... August 2005). "Serous cystadenocarcinoma of the pancreas: management of a rare entity". Pancreas. 31 (2): 182-187. doi:10.1097/ ... King JC, Ng TT, White SC, Cortina G, Reber HA, Hines OJ (October 2009). "Pancreatic serous cystadenocarcinoma: a case report ... with the majority of microcystic pancreatic masses representing alternate disease processes such as the more benign serous ...
https://en.wikipedia.org/wiki/Serous_cystadenocarcinoma
Papillary serous cystadenocarcinomaPapillary serous cystadenocarcinoma
Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer ... Papillary serous cystadenocarcinomas may exhibit psammoma bodies upon histopathology. Papillary serous cystadenoma Kosary CL ( ... Papillary serous cystadenocarcinomas are the most common form of malignant ovarian cancer making up 26 percent of ovarian ...
https://en.wikipedia.org/wiki/Papillary_serous_cystadenocarcinoma
Ovarian serous cystadenomaOvarian serous cystadenoma
"Ovarian serous cystadenocarcinoma". , Radiology Reference Article. Radiopaedia.org. Retrieved 2019-09-21. v t e v t e (Articles ... Serous ovarian cystadenocarcinomas account for ~25% of serous tumours. Ovarian cancer Pancreatic serous cystadenoma Serous ... also called serous borderline tumours, that may transform into serous carcinoma. Serous cystadenomas (of the ovary) are not ... Ovarian serous cystadenoma, also (less precisely) known as serous cystadenoma, is the most common ovarian neoplasm, ...
https://en.wikipedia.org/wiki/Ovarian_serous_cystadenoma
Fibroblast growth factor receptor 1Fibroblast growth factor receptor 1
... of ovarian Papillary serous cystadenocarcinoma (almost all amplifications); ~5% of colorectal cancers (~60 amplifications, 40% ...
https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor_1
CystadenocarcinomaCystadenocarcinoma
Bilateral presentation is common with serous cystadenocarcinoma. Papillary serous cystadenocarcinoma Ovarian serous cystadenoma ... "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". Journal of Gastrointestinal Surgery. 13 (10 ... Cystadenocarcinoma is a malignant form of a cystadenoma and is a cancer derived from glandular epithelium, in which cystic ... A cystadenocarcinoma contains complex multi-loculated cyst but with exuberant solid areas in places. It usually presents with ...
https://en.wikipedia.org/wiki/Cystadenocarcinoma
Pancreatic serous cystadenomaPancreatic serous cystadenoma
... "serous cystadenocarcinoma".[citation needed] These lesions rarely require surgery unless they are symptomatic or the diagnosis ... Those that are benign, that have not spread to other organs, are designated "serous cystadenoma". Serous cystadenomas can be ... There are some exceptions; rare case reports have described isolated malignant serous cystadenocarcinomas. In addition, serous ... Pancreatic serous cystadenoma is a benign tumour of pancreas. It is usually found in the tail of the pancreas, and may be ...
https://en.wikipedia.org/wiki/Pancreatic_serous_cystadenoma
Psammoma bodyPsammoma body
Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer ... Papillary thyroid carcinoma Papillary renal cell carcinoma Ovarian papillary serous cystadenoma and cystadenocarcinoma ... Endometrial adenocarcinomas (Papillary serous carcinoma ~3%-4%) Meningiomas, in the central nervous system Peritoneal and ...
https://en.wikipedia.org/wiki/Psammoma_body
Ovarian cancerOvarian cancer
Low-grade serous carcinoma is less aggressive than high-grade serous carcinomas, though it does not typically respond well to ... Mucinous tumors include mucinous adenocarcinoma and mucinous cystadenocarcinoma. Mucinous adenocarcinomas make up 5-10% of ... Serous carcinomas are thought to begin in the Fallopian tube. High grade serous carcinoma accounts for 75% of all epithelial ... Serous carcinomas may develop from serous tubal intraepithelial carcinoma, rather than developing spontaneously from ovarian ...
https://en.wikipedia.org/wiki/Ovarian_cancer
SK-OV-3SK-OV-3
... ovarian cancer cell line derived from the ascites of a 64-year-old Caucasian female with an ovarian serous cystadenocarcinoma. ...
https://en.wikipedia.org/wiki/SK-OV-3
Leukotriene B4 receptor 2Leukotriene B4 receptor 2
... the Serous cystadenocarcinoma type of ovarian cancer, and uterine cervical carcinoma. Other studies have implicated BLT2 in ...
https://en.wikipedia.org/wiki/Leukotriene_B4_receptor_2
Estrogen receptor betaEstrogen receptor beta
... ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues". The Journal ...
https://en.wikipedia.org/wiki/Estrogen_receptor_beta
Surface epithelial-stromal tumorSurface epithelial-stromal tumor
75% are benign or of borderline malignancy, and 25% are malignant The malignant form of this tumor, serous cystadenocarcinoma, ... lined by tall, columnar, ciliated epithelial cells filled with clear serous fluid the term serous which originated as a ... Malignant serous tumors occur later in life on average, although somewhat earlier in familial cases. 20% of benign, 30% of ... The overall prognosis is somewhat worse than for serous or mucinous tumors, and the 5-year survival rate for patients with ...
https://en.wikipedia.org/wiki/Surface_epithelial-stromal_tumor
List of MeSH codes (C04)List of MeSH codes (C04)
... cystadenocarcinoma, papillary MeSH C04.557.470.200.025.480.240 - cystadenocarcinoma, serous MeSH C04.557.470.200.025.540 - ... cystadenocarcinoma, papillary MeSH C04.557.470.590.480.240 - cystadenocarcinoma, serous MeSH C04.557.470.590.485 - cystadenoma ... cystadenocarcinoma MeSH C04.557.470.200.025.480.225 - cystadenocarcinoma, mucinous MeSH C04.557.470.200.025.480.230 - ... cystadenocarcinoma MeSH C04.557.470.590.480.225 - cystadenocarcinoma, mucinous MeSH C04.557.470.590.480.230 - ...
https://en.wikipedia.org/wiki/List_of_MeSH_codes_(C04)
PancreatectomyPancreatectomy
... mucinous/serous) Cystadenocarcinoma Islet cell tumors (neuroendocrine tumors) Papillary cystic neoplasms Lymphoma Acinar cell ...
https://en.wikipedia.org/wiki/Pancreatectomy
International Cancer Genome ConsortiumInternational Cancer Genome Consortium
... ovarian serous cystadenocarcinoma, lung squamous cell carcinoma, adrenocortical carcinoma, Diffuse Large B-cell lymphoma, ... Serous cystadenocarcinoma Canada: Pancreatic cancer - Ductal adenocarcinoma and prostate cancer - adenocarcinoma China: Gastric ...
https://en.wikipedia.org/wiki/International_Cancer_Genome_Consortium
International Classification of Diseases for OncologyInternational Classification of Diseases for Oncology
NOS Serous cystoma Serous microcystic adenoma M8441/3 Serous cystadenocarcinoma, NOS (C56.9) Serous adenocarcinoma, NOS Serous ... M8460/0 Papillary serous cystadenoma, NOS (C56.9) M8460/3 Papillary serous cystadenocarcinoma (C56.9) Papillary serous ... Serous cystadenofibroma of borderline malignancy M9014/3 Serous adenocarcinofibroma Malignant serous adenofibroma Serous ... M8461/3 Serous surface papillary carcinoma (C56.9) Primary serous papillary carcinoma of peritoneum (C48.1) M8462/1 Serous ...
https://en.wikipedia.org/wiki/International_Classification_of_Diseases_for_Oncology
Testicular cancerTesticular cancer
... borderline malignancy Serous carcinoma Well differentiated endometrioid tumor Mucinous cystadenoma Mucinous cystadenocarcinoma ... lymphoma of the testes pediatric-type follicular lymphoma of the testes Carcinoid Tumors of ovarian epithelial types Serous ...
https://en.wikipedia.org/wiki/Testicular_cancer
CystadenomaCystadenoma
ISBN 978-1-4160-2999-1. Serous cystadenoma of pancreas at eMedicine Biliary cystadenoma/cystadenocarcinoma at eMedicine v t e ( ... When malignant, it is called cystadenocarcinoma. When not otherwise specified, the ICD-O coding is 8440/0. However, the ... following classifications also exist: serous cystadenoma (8441-8442) papillary cystadenoma (8450-8451, 8561) mucinous ...
https://en.wikipedia.org/wiki/Cystadenoma
The Cancer Genome AtlasThe Cancer Genome Atlas
... ovarian serous cystadenocarcinoma, lung squamous cell carcinoma, adrenocortical carcinoma, Diffuse Large B-cell lymphoma, ... Three tumor types were explored during the pilot phase, glioblastoma multiforme (GBM) and high-grade serous ovarian ... and ovarian serous adenocarcinoma. In 2009, it expanded into phase II, which planned to complete the genomic characterization ... and exome sequencing of 316 tumor samples of high grade serous ovarian cancer in Nature in June 2011. The researchers found ...
https://en.wikipedia.org/wiki/The_Cancer_Genome_Atlas
Cystic lesions of the pancreasCystic lesions of the pancreas
Pancreatic serous cystadenoma Pancreatic serous cystadenocarcinoma Pancreatic mucinous cystic tumors (13.4%) Pancreatic ... Pancreatic intraductal papillary mucinous tumors (most common diagnosis - 52.6%) Pancreatic serous cystic tumors (20.6%) ... mucinous cystadenoma Pancreatic mucinous cystadenocarcinoma (Articles needing additional references from January 2017, All ...
https://en.wikipedia.org/wiki/Cystic_lesions_of_the_pancreas
Mucinous cystadenomaMucinous cystadenoma
Biliary cystadenoma and cystadenocarcinoma constitute less than 5% of intrahepatic cysts originating from the bile duct. ... On an average, mucinous accounts for 40-50% of cystic tumors, and serous cytadenoma accounts for 30% of it. Mucinous ...
https://en.wikipedia.org/wiki/Mucinous_cystadenoma
2014 Ju-Jitsu World Championships2014 Ju-Jitsu World Championships
The 2014 Ju-Jitsu World Championship were the 12th edition of the Ju-Jitsu World Championships, and were held in Paris, France from November 28 to November 30, 2014. 28.11.2014 - Men's and Women's Fighting System, Men's and Women's Jiu-Jitsu (ne-waza), Men's Duo System - Classic 29.11.2014 - Men's and Women's Fighting System, Men's and Women's Jiu-Jitsu (ne-waza), Women's Duo System - Classic 30.11.2014 - Men's Jiu-Jitsu (ne-waza), Mixed Duo System - Classic, Team event Vincent MATCZAK (2014-09-30). "4TH INVITAION TO WORLD CHAMPIONSHIP 2014" (PDF). Retrieved 2019-11-28.[dead link] Online results Official results (PDF) Mixed team event results (PDF) (All articles with dead external links, Articles with dead external links from April 2022, Ju-Jitsu World Championships, 2014 in French sport ...
https://en.wikipedia.org/wiki/2014_Ju-Jitsu_World_Championships
Bolley JohnsonBolley Johnson
Bolley L. "Bo" Johnson (born November 15, 1951) is an American politician from the state of Florida. A member of the Democratic Party, Johnson was a member of the Florida House of Representatives, and served as the Speaker of the Florida House of Representatives. Johnson is from Milton, Florida. His father and grandfather served as county commissioners for Santa Rosa County, Florida. Johnson graduated from Milton High School, and became the first member of his family to attend college. He received his bachelor's degree from Florida State University. Johnson volunteered for Mallory Horne when Horne served as the president of the Florida Senate. At the age of 22, Johnson met Lawton Chiles, then a member of the United States Senate, who hired him as a legislative aide in 1973. Johnson was elected to the Florida House of Representatives, representing the 4th district from November 7, 1978 to November 3, 1992. He also served the 1st district from November 3, 1992 to November 8, 1994. He became the ...
https://en.wikipedia.org/wiki/Bolley_Johnson
Dont Say NoDon't Say No
... may refer to: Don't Say No (Billy Squier album), a 1981 album by American rock singer Billy Squier, and its title track Don't Say No (Seohyun EP), a 2016 extended play by South Korean pop singer Seohyun, and its title track "Don't Say No" (Tom Tom Club song), from the 1988 album Boom Boom Chi Boom Boom "Don't Say No", by Robbie Williams from the 2005 album Intensive Care "Don't Say No Tonight", a 1985 single by Eugene Wilde This disambiguation page lists articles associated with the title Don't Say No. If an internal link led you here, you may wish to change the link to point directly to the intended article. (Disambiguation pages with short descriptions, Short description is different from Wikidata, All article disambiguation pages, All disambiguation pages, Disambiguation pages ...
https://en.wikipedia.org/wiki/Don't_Say_No
Dewoitine D.371Dewoitine D.371
The Dewoitine 37 was the first of a family of 1930s French-built monoplane fighter aircraft. The D.37 was a single-seat aircraft of conventional configuration. Its fixed landing gear used a tailskid. The open cockpit was located slightly aft of the parasol wing. The radial engine allowed for a comparatively wide fuselage and cockpit. Design of this machine was by SAF-Avions Dewoitine but owing to over work at that companies plant at the time, manufacture of the D.37/01 was transferred to Lioré et Olivier. They were high-wing monoplanes of all-metal construction with valve head blisters on their engine cowlings. The first prototype flew in October 1931. Flight testing resulted in the need for multiple revisions in both engine and airframe, so it was February 1934 before the second prototype flew. Its performance prompted the French government to order for 28 for the Armée de l'Air and Aéronavale. The Lithuanian government ordered 14 that remained in service with their Air Force until 1936, ...
https://en.wikipedia.org/wiki/Dewoitine_D.371
Noor-ul-AinNoor-ul-Ain
The Noor-ul-Ain (Persian: نور العين, lit. 'the light of the eye') is one of the largest pink diamonds in the world, and the centre piece of the tiara of the same name. The diamond is believed to have been recovered from the mines of Golconda, Hyderabad in India. It was first in possession with the nizam Abul Hasan Qutb Shah, later it was given as a peace offering to the Mughal emperor Aurangazeb when he defeated him in a siege. It was brought into the Iranian Imperial collection after the Persian king Nader Shah Afshar looted Delhi in the 18th century.[citation needed] The Noor-ul-Ain is believed to have once formed part of an even larger gem called the Great Table diamond. That larger diamond is thought to have been cut in two, with one section becoming the Noor-ul-Ain and the other the Daria-i-Noor diamond. Both of these pieces are currently part of the Iranian Crown Jewels. The Noor-ul-Ain is the principal diamond mounted in a tiara of the same name made for Iranian Empress Farah ...
https://en.wikipedia.org/wiki/Noor-ul-Ain
Benoist Land Tractor Type XIIBenoist Land Tractor Type XII
The Benoist Land Tractor Type XII was one of the first enclosed cockpit, tractor configuration aircraft built. Benoist used "Model XII" to several aircraft that shared the same basic engine and wing design, but differed in fuselage and control surfaces. The Type XII was a tractor-engined conversion of the model XII headless pusher aircraft that resembled the Curtiss pusher aircraft. Demonstration pilots used Benoist aircraft to demonstrate the first parachute jumps, and the tractor configuration was considered much more suitable for the task. The first example named the "Military Plane" had a small box frame covered fuselage that left the occupants mostly exposed to the wind. The later model XII "Cross Country Plane" had a full fuselage that occupants sat inside of. The first tractor biplane used a wooden fuselage with a small seat on top. The wings were covered with a Goodyear rubberized cloth. The first model XII was built in the spring of 1912. On 1 March 1912, Albert Berry used a headless ...
https://en.wikipedia.org/wiki/Benoist_Land_Tractor_Type_XII
Santa Cruz BarillasSanta Cruz Barillas
... (also known as Yalmotx in Qʼanjobʼal) is a town, with a population of 17,166 (2018 census), and a municipality in the Guatemalan department of Huehuetenango. It is situated at 1450 metres above sea level. It covers a terrain of 1,174 km². The annual festival is April 29-May 4. Barillas has a tropical rainforest climate (Af) with heavy to very heavy rainfall year-round and extremely heavy rainfall from June to August. Citypopulation.de Population of departments and municipalities in Guatemala Citypopulation.de Population of cities & towns in Guatemala "Climate: Barillas". Climate-Data.org. Retrieved July 26, 2020. Muni in Spanish Website of Santa Cruz Barillas Coordinates: 15°48′05″N 91°18′45″W / 15.8014°N 91.3125°W / 15.8014; -91.3125 v t e (Articles with short description, Short description is different from Wikidata, Pages using infobox settlement with no coordinates, Articles containing Q'anjob'al-language text, Coordinates on Wikidata, ...
https://en.wikipedia.org/wiki/Santa_Cruz_Barillas
Maria Margaret PollenMaria Margaret Pollen
Maria Margaret La Primaudaye Pollen (10 April 1838 - c. 1919), known as Minnie, was a decorative arts collector. As Mrs John Hungerford Pollen, she became known during the early-twentieth century as an authority on the history of textiles, publishing Seven Centuries of Lace in 1908. Maria Margaret La Primaudaye was born into a Huguenot family on 10 April 1838, the third child of the Revd Charles John La Primaudaye, a descendant of Pierre de La Primaudaye. She was educated in Italy. Her family converted to Catholicism in 1851, and it was in Rome that her father met another recent English convert, John Hungerford Pollen, previously an Anglican priest and a decorative artist. She became engaged to Pollen, who was then seventeen years her senior, in the summer of 1854, and was married in the church of Woodchester monastery, near Stroud, Gloucester, on 18 September 1855. The Pollens initially settled in Dublin, where John Hungerford Pollen had been offered the professorship of fine arts at the ...
https://en.wikipedia.org/wiki/Maria_Margaret_Pollen
Ronald FoglemanRonald Fogleman
Ronald Robert Fogleman (born January 27, 1942) is a retired United States Air Force general who served as the 15th Chief of Staff of the Air Force from 1994 to 1997 and as Commanding General of the United States Transportation Command from 1992 to 1994. A 1963 graduate from the United States Air Force Academy, he holds a master's degree in military history and political science from Duke University. A command pilot and a parachutist, he amassed more than 6,800 flying hours in fighter, transport, tanker and rotary wing aircraft. He flew 315 combat missions and logged 806 hours of combat flying in fighter aircraft. Eighty of his missions during the Vietnam War were as a "Misty FAC" in the F-100F Super Sabre at Phù Cát Air Base, South Vietnam between 25 December 1968 and 23 April 1969. Fogleman was shot down in Vietnam in 1968, while piloting an F-100. He was rescued by clinging to an AH-1 Cobra attack helicopter that landed at the crash site. In early assignments he instructed student pilots, ...
https://en.wikipedia.org/wiki/Ronald_Fogleman
Collision tumor of ovary: a rare combination of dysgerminoma and serous cystadenocarcinoma | Bangladesh Journal of...Collision tumor of ovary: a rare combination of dysgerminoma and serous cystadenocarcinoma | Bangladesh Journal of...
Collision tumor of ovary: a rare combination of dysgerminoma and serous cystadenocarcinoma Authors. * Sanjay Sengupta Associate ... collision tumor, dysgerminoma, serous cystadenocarcinoma Abstract. Collision tumors of ovary are rare neoplasms and most ... Combination of papillary serous cystadenocarcinoma and dysgerminoma was yet to be reported. A twenty years female patient ... Microscopically it was diagnosed as a collision tumor of ovary composed of dysgerminoma and serous cystadenocarcinoma. Mixed ...
https://www.banglajol.info/index.php/BJMS/article/view/14955
IMSEAR at SEARO: Collision tumor of ovary: a rare combination of dysgerminoma and serous cystadenocarcinoma.
Microscopically it was diagnosed as a collision tumor of ovary composed of dysgerminoma and serous cystadenocarcinoma. Mixed ... Collision tumor of ovary: a rare combination of dysgerminoma and serous cystadenocarcinoma. ... a rare combination of dysgerminoma and serous cystadenocarcinoma. Bangladesh Journal of Medical Science. 2014; 13(2): 224-227. ... Combination of papillary serous cystsdenocarcinoma and dysgerminoma was yet to be reported. A twenty years female patient ...
https://imsear.searo.who.int/handle/123456789/167632
TMEM158 promotes the proliferation and migration of glioma cells via STAT3 signaling in glioblastomas | Cancer Gene TherapyTMEM158 promotes the proliferation and migration of glioma cells via STAT3 signaling in glioblastomas | Cancer Gene Therapy
... ovarian serous cystadenocarcinoma, OV; pancreatic adenocarcinoma, PAAD; rectum adenocarcinoma, READ; skin cutaneous melanoma, ...
https://www.nature.com/articles/s41417-021-00414-5?error=cookies_not_supported&code=e5d19d75-acec-4aba-adcd-89945ee0f0ec
Evaluating cell lines as tumour models by comparison of genomic profilesEvaluating cell lines as tumour models by comparison of genomic profiles
Cystadenocarcinoma, Serous / genetics* * Cystadenocarcinoma, Serous / metabolism * Female * Gene Dosage * Gene Expression ... reveals pronounced differences in molecular profiles between commonly used ovarian cancer cell lines and high-grade serous ...
https://pubmed.ncbi.nlm.nih.gov/23839242/?dopt=Abstract
A Study of Adavosertib as Treatment for Uterine Serous Carcinoma - Full Text View - ClinicalTrials.govA Study of Adavosertib as Treatment for Uterine Serous Carcinoma - Full Text View - ClinicalTrials.gov
Cystadenocarcinoma, Serous. Neoplasms, Glandular and Epithelial. Neoplasms by Histologic Type. Neoplasms. Cystadenocarcinoma. ... A Study of Adavosertib as Treatment for Uterine Serous Carcinoma (ADAGIO). The safety and scientific validity of this study is ... Neoplasms, Cystic, Mucinous, and Serous. Adavosertib. Enzyme Inhibitors. Molecular Mechanisms of Pharmacological Action. ... in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum- ...
https://clinicaltrials.gov/ct2/show/NCT04590248?term=ADAGIO+D601HC00002&draw=2&rank=1
CN113168886A - 用于使用神经网络进行种系和体细胞变
208000004548 Serous Cystadenocarcinoma Diseases 0.000 description 2 * 208000003721 Triple Negative Breast Neoplasms Diseases ...
https://patents.google.com/patent/CN113168886A/ja
Pancreatic Pseudocysts: Practice Essentials, Background, PathophysiologyPancreatic Pseudocysts: Practice Essentials, Background, Pathophysiology
A comparison of pseudocysts, serous cystadenomas, mucinous cystic neoplasms, and mucinous cystadenocarcinoma. Ann Surg. 1993 ...
https://emedicine.medscape.com/article/184237-overview
CholangiocarcinomaCholangiocarcinoma
Cystic, Mucinous And Serous (8440-8499). (Mucoepidermoid carcinoma - Cystadenoma/Cystadenocarcinoma/Pseudomyxoma peritonei - ...
https://www.bionity.com/en/encyclopedia/Cholangiocarcinoma.html
The Role of CBLL1 in the Prognosis and Immune Infiltration of Pan-Cancer | Research SquareThe Role of CBLL1 in the Prognosis and Immune Infiltration of Pan-Cancer | Research Square
4C); PFI in patients with GBM, KIRC, Ovarian serous cystadenocarcinoma (OV), THYM and UVM (Fig. 4D). ...
https://www.researchsquare.com/article/rs-91598/v1
Cells | Free Full-Text | Three-Dimensional Genome Organization in Breast and Gynecological Cancers: How Chromatin Folding...Cells | Free Full-Text | Three-Dimensional Genome Organization in Breast and Gynecological Cancers: How Chromatin Folding...
... including invasive breast carcinoma and ovarian serous cystadenocarcinoma. The target genes of miRNAs regulated by enhancers ...
https://www.mdpi.com/2073-4409/11/1/75
Find Research outputs - Manipal Academy of Higher Education, Manipal, India
MRI classification and characterization of complex ovarian massesMRI classification and characterization of complex ovarian masses
1 Given their varied imaging appearance these malignancies have overlapping features with serous cystadenocarcinoma, as both ... Serous cystadenocarcinomas, the malignant variant of the serous epithelial neoplasm, are among the high-grade cancers seen in ... Serous cystadenomas are benign epithelial tumors seen in the 4th to 5th decade. Generally smaller than mucinous tumors, these ... They are larger than serous neoplasms, with a "honey-comb" of locules with varied signal intensities separated by thin ...
https://appliedradiology.com/communities/Breast-Imaging/mri-classification-and-characterization-of-complex-ovarian-masses
Simple Ovarian Cysts on Ultrasound Need No Further MonitoringSimple Ovarian Cysts on Ultrasound Need No Further Monitoring
... papillary serous cyst-adenocarcinoma (36.6%), endometrioid carcinoma (12.0%), serous cystadenocarcinoma (10.6%), clear cell ...
https://www.medscape.com/viewarticle/904776
Calprotectin and Calgranulin C as Biomarkers of Pancreatic Tumors: Baseline Levels and Level Changes after SurgeryCalprotectin and Calgranulin C as Biomarkers of Pancreatic Tumors: Baseline Levels and Level Changes after Surgery
... mucinous cystadenocarcinoma; AVC: ampulla of Vater carcinoma; DBDC: distal bile duct carcinoma; IPMN: intraductal papillary ... serous cystadenomas or pancreatic pseudocysts) or histologically confirmed malignant pancreatic tumors, including ductal ... adenocarcinoma, neuroendocrine tumors, and mucinous cystadenocarcinoma; 15 patients with biliary carcinoma, inconclusive ...
https://www.hindawi.com/journals/mi/2019/6985703/
Ovarian collision tumor consisting of sclerosing stromal tumor and mature cystic teratoma complicated with Meigs syndrome: A...Ovarian collision tumor consisting of sclerosing stromal tumor and mature cystic teratoma complicated with Meigs syndrome: A...
Ovarian serous cystadenoma usually deteriorates to form serous cystadenocarcinoma, which has distinct papillary protrusions on ... Bige O, Demir A, Koyuncuoglu M, Secil M, Ulukus C and Saygili U: Collision tumor: Serous cystadenocarcinoma and dermoid cyst in ... Seo EJ, Kwon HJ and Shim SI: Ovarian serous cystadenoma associated with Sertoli-Leydig cell tumor-a case report. J Korean Med ... Serous cystadenomas are smaller than mucinous cystadenomas, but they frequently have calcifications and papillary soft tissue ...
https://www.spandidos-publications.com/10.3892/ol.2022.13563?text=fulltext
HuGE Navigator|HuGE Literature Finder|PHGKBHuGE Navigator|HuGE Literature Finder|PHGKB
No article was found for Cystadenocarcinoma, Serous and TERT[original query]. File Formats Help:. How do I view different file ...
https://phgkb.cdc.gov/PHGKB/searchSummary.action?firstQuery=Cystadenocarcinoma,%20Serous+and+TERT&Mysubmit=Search
Serum vitamin D deficiency and risk of epithelial ovarian cancer in Lagos, Nigeria - ecancerSerum vitamin D deficiency and risk of epithelial ovarian cancer in Lagos, Nigeria - ecancer
The most common histological type of EOC in the study was serous cystadenocarcinoma (80.0%), whereas the least common was ...
https://ecancer.org/en/journal/article/1078-serum-vitamin-d-deficiency-and-risk-of-epithelial-ovarian-cancer-in-lagos-nigeria
Prognostic and immune regulating roles of YIF1B in Pan-Cancer: a potential target for both survival and therapy response...
... ovarian serous cystadenocarcinoma (OV), skin cutaneous melanoma (SKCM) and uveal melanoma (UVM), among which YIF1B had the ... D) DSS difference between groups in ovary serous cystuadenocarcinoma (OV). (E) DSS difference between groups in KIRC. (F) DSS ... D) DSS difference between groups in ovary serous cystuadenocarcinoma (OV). (E) DSS difference between groups in KIRC. (F) DSS ...
https://port.silverchair.com/bioscirep/article/40/7/BSR20201384/225759/Prognostic-and-immune-regulating-roles-of-YIF1B-in
Female reproductive system Archives | USMLE XLFemale reproductive system Archives | USMLE XL
Female- Serous cystadenocarcinoma. A patient presents with abdominal discomfort, and an ultrasonogram (USG) reveals an ovarian ...
https://usmle-xl.com/usmle-xl-subject/female-reproductive-system/
FFCP PHASE1:Hg19::chr3:197205905..197205924,+ - resource browserFFCP PHASE1:Hg19::chr3:197205905..197205924,+ - resource browser
serous cystadenocarcinoma cell line:HTOA.CNhs11827.10693-109F9. 0.22. signet ring carcinoma cell line:Kato III.CNhs10753.10436- ... serous adenocarcinoma cell line:JHOS-2.CNhs11746.10639-108I9. 0.00. serous adenocarcinoma cell line:SK-OV-3-R after co-culture ... mucinous cystadenocarcinoma cell line:MCAS.CNhs11873.10784-110H1. 0.00. mycosis fungoides, T cell lymphoma cell line:HuT 102 ... serous adenocarcinoma cell line:SK-OV-3-R, biol_rep1.CNhs13099.11841-124H5. 1.91. ...
https://fantom.gsc.riken.jp/5/sstar/FFCP_PHASE1:Hg19::chr3:197205905..197205924,%2B
FFCP PHASE2:Hg19::chr6:71665623..71665630,- - resource browserFFCP PHASE2:Hg19::chr6:71665623..71665630,- - resource browser
serous cystadenocarcinoma cell line:HTOA.CNhs11827.10693-109F9. 0.00. signet ring carcinoma cell line:Kato III.CNhs10753.10436- ... serous adenocarcinoma cell line:JHOS-2.CNhs11746.10639-108I9. 0.00. serous adenocarcinoma cell line:SK-OV-3-R after co-culture ... mucinous cystadenocarcinoma cell line:MCAS.CNhs11873.10784-110H1. 0.00. mycosis fungoides, T cell lymphoma cell line:HuT 102 ... serous adenocarcinoma cell line:SK-OV-3-R, biol_rep1.CNhs13099.11841-124H5. 0.00. ...
https://fantom.gsc.riken.jp/5/sstar/FFCP_PHASE2:Hg19::chr6:71665623..71665630,-
BMB ReportsBMB Reports
TRPs in Ovarian Serous Cystadenocarcinoma: The Expression Patterns, Prognostic Roles, and Potential Therapeutic Targets. Front ...
https://www.bmbreports.org/journal/citedBy.html?doi=10.5483/BMBRep.2020.53.3.016
Ubiquitin-specific peptidase 37: an important cog in the oncogenic machinery of cancerous cells | Journal of Experimental &...Ubiquitin-specific peptidase 37: an important cog in the oncogenic machinery of cancerous cells | Journal of Experimental &...
... ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), pheochromocytoma and paraganglioma (PCPG), prostate ...
https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02163-7
MeSH BrowserMeSH Browser
Cystadenocarcinoma, Papillary [C04.557.470.200.025.480.230] * Cystadenocarcinoma, Serous [C04.557.470.200.025.480.240] ... Cystadenocarcinoma [C04.557.470.590.480] * Cystadenocarcinoma, Mucinous [C04.557.470.590.480.225] * Cystadenocarcinoma, ... Cystadenocarcinoma [C04.557.470.200.025.480] * Cystadenocarcinoma, Mucinous [C04.557.470.200.025.480.225] * ... Cystadenocarcinoma Preferred Term Term UI T010250. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1966). ...
https://meshb.nlm.nih.gov/record/ui?ui=D003536
HuGE Navigator|Genopedia|PHGKBHuGE Navigator|Genopedia|PHGKB
Cystadenocarcinoma, Serous 1 0 Diabetes Mellitus, Type 2 1 0 Lymphoma, Large B-Cell, Diffuse 1 0 ...
https://phgkb.cdc.gov/PHGKB/huGEPedia.action?firstQuery=KIR2DL2&geneID=3803&typeSubmit=GO&check=y&typeOption=gene&which=2&pubOrderType=pubD
Code System Concept
Papillary serous cystadenocarcinoma Active Synonym false false 3852374018 Papillary serous adenocarcinoma Active Synonym false ...
https://phinvads.cdc.gov/vads/ViewCodeSystemConcept.action?oid=2.16.840.1.113883.6.96&code=90725004
DeCSDeCS
Cystadenocarcinomas, Serous. Serous Cystadenocarcinoma. Serous Cystadenocarcinomas. Tree number(s):. C04.557.470.200.025.480. ... Cystadenocarcinoma, Serous - Preferred Concept UI. M0027515. Scope note. A malignant cystic or semicystic neoplasm. It often ... patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma ... patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma ...
https://decs.bvsalud.org/en/ths/resource/?id=31527
Search | African Index Medicus (AIM)Search | African Index Medicus (AIM)
... serous cystadenocarcinoma (12.5); malignant teratoma 2(5) and endodermal sinus tumour (5). There were 2 cases of metastatic ... Mucinous cystadenocarcinoma was the ommonest malignant ovarian tumour 14(35) and was closely followed by granulosa cell tumour ...
https://search.bvsalud.org/aimafro/?lang=en&q=mh:Ovarian+Neoplasms
The Cancer Gene Index Gene-Disease and Gene-Compound XML Documents - ICR - Cancer Gene Index - NCI WikiThe Cancer Gene Index Gene-Disease and Gene-Compound XML Documents - ICR - Cancer Gene Index - NCI Wiki
... ovarian serous cystadenocarcinoma and ovarian serous papillary adenocarcinoma and the parent terms malignant ovarian serous ... ovarian serous adenocarcinoma), and click the Search button (3). If you need help finding your gene, disease, or compound term ... tumor, ovarian adenocarcinoma, and serous adenocarcinoma. Alternatively, if you would like to view where your term fits in ...
https://wiki.nci.nih.gov/display/cageneindex/The+Cancer+Gene+Index+Gene-Disease+and+Gene-Compound+XML+Documents
Papillary serous cystadenocarcinomaMucinous cystadenocarcinomaCystadenomaCarcinomaAdenocarcinomaDysgerminoma and serous cystadenocarcinomaPancreaticTumorsNeoplasmsFollowed by mucinousHigh-grade serousCommonest benign tumourCystadenocarcinomasCysticTumoursCystadenomasCancersNeoplasticFoundCase reportTreatmentPresentAdenocarcinomaPancreaticEndometrioidTumorPeritonealCystadenocarcinomasBenignHGSOCMalignant ovarianCancerCaseArticleType
Papillary serous cystadenocarcinoma3
  • Combination of papillary serous cystadenocarcinoma and dysgerminoma was yet to be reported. (banglajol.info)
  • Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. (bvsalud.org)
  • Nagar YS , Singh S , Sawlani V , Pal L , Dimri K , Lal P . Primary papillary serous cystadenocarcinoma of broad ligament . (autopsyandcasereports.org)
Mucinous cystadenocarcinoma5
  • Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. (ucbraid.org)
  • Mucinous cystadenocarcinoma is the second most common etiology of appendiceal mucocele. (biomedcentral.com)
  • We report a relatively rare case of a giant appendiceal mucocele caused by mucinous cystadenocarcinoma, which occupied the entire abdomen of an adult woman. (biomedcentral.com)
  • There were 28.4% serous cystadenoma, 21% mucinous cystadenoma, 6.2% intraductal papillary tumors, 8.6% solid pseudopapillary tumors, 1.2% neuroendocrinal tumor, 3.7% ductal adenocarcinoma, and 30.9% mucinous cystadenocarcinoma. (saudijgastro.com)
  • Histology reported a mucinous cystadenocarcinoma of low malignant potential. (medscape.com)
Cystadenoma3
  • The commonest benign tumor was serous cystadenoma(40/66) followed by dermoid cyst(12/66). (ijcrr.com)
  • The commonest benign tumour was serous cystadenoma and malignant was serous cystadenocarcinoma. (ijcrr.com)
  • serous tumors (including serous cystadenoma (SCA) and cystadenocarcinoma), mucinous tumors (including mucinous cystadenomas (MCN), mucinous cystadenocarcinomas, intraductal papillary adenomas, and intraductal papillary adenocarcinoma) and solid pseudopapillary tumors (SPT). (saudijgastro.com)
Carcinoma3
  • This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC. (clinicaltrials.gov)
  • Serous cystadenocarcinoma was the commonest malignant tumour followed closelyby endometrioid carcinoma and granulosa cell tumour. (edu.pk)
  • Hemalatha AL , Rao SM , Kumar DB , Vani M . Papillary serous carcinoma of the broad ligament: a rare case report . (autopsyandcasereports.org)
Adenocarcinoma1
  • There are no common causative somatic gene mutations, outside of TP53 alterations in serous adenocarcinoma and KRAS, BRAF and PTEN in mucinous, endometrioid, and low grade serous cancers, suggested to be associated with the pathogenesis of EOC [ 2 ]. (oncotarget.com)
Dysgerminoma and serous cystadenocarcinoma2
  • Microscopically it was diagnosed as a collision tumor of ovary composed of dysgerminoma and serous cystadenocarcinoma. (banglajol.info)
  • Sengupta S, Pal S, Biswas B, Chakrabarti S, Bose K, Jana S. Collision tumor of ovary: a rare combination of dysgerminoma and serous cystadenocarcinoma. (who.int)
Pancreatic1
  • The most common pancreatic cysts were serous and mucinous cysts. (saudijgastro.com)
Tumors1
  • Serous cystadenomas are benign epithelial tumors seen in the 4th to 5th decade. (appliedradiology.com)
Neoplasms1
  • They are larger than serous neoplasms, with a "honey-comb" of locules with varied signal intensities separated by thin septations and no solid components. (appliedradiology.com)
Followed by mucinous1
  • The commonest malignant tumour was serous cystadenocarcinoma (5/16) followed by mucinous cystadenocarcinomama (3/16). (ijcrr.com)
High-grade serous3
  • Our comparison of copy-number changes, mutations and mRNA expression profiles reveals pronounced differences in molecular profiles between commonly used ovarian cancer cell lines and high-grade serous ovarian cancer tumour samples. (nih.gov)
  • Genetic and immunophenotype analyses have shown that high-grade serous ovarian cancer, the most frequent histological type and the one with the worst prognosis, originates mainly from fallopian tube epithelium, while endometrioid and clear-cell cancers originate from the endometrium. (viamedica.pl)
  • In particular, we would like to alert researchers to the fact that the most popular cell lines SKOV3 and A2780 do not represent a suitable model for studies on high-grade serous ovarian cancer. (viamedica.pl)
Commonest benign tumour1
  • Benign serous cysts were the commonest benign tumour followed by mature cystic teratomaand mucinous cyst. (edu.pk)
Cystadenocarcinomas1
  • Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (nih.gov)
Cystic1
Tumours1
  • There was no significant increase in serous tumours, a modest increase in mucinous tumours, but a substantial increase in endometrioid (RR = 1.49, 95% CI: 1.18-1.89) and clear-cell tumours (RR = 1.68, 1.29-2.20). (ox.ac.uk)
Cystadenomas1
  • Two types of hepatic cystadenomas are described pathologically, as follows: mucinous and serous. (medscape.com)
Cancers4
  • L'objectif de cette étude était de déterminer la fréquence des cancers gynécologiques en pratique oncologique à Lomé et d'en étudier les aspects épidémiologiques et histo-cliniques. (bvsalud.org)
  • Il s'agitd'une étude rétrospective et descriptive portant sur tous les cancers gynécologiques reçus en oncologie entre le 1erJanvier 2016 et le 31 Décembre 2021. (bvsalud.org)
  • ces cancers ont ete diagnostiques au stade avance d'ou les difficultes dans leur prise en charge chirurgicale. (bvsalud.org)
  • En consequence notre objectif a ete d'etudier la place et les caracteres de la chirurgie dans la prise en charge de ces cancers. (bvsalud.org)
Neoplastic1
  • The commonest non-neoplastic lesion was Luteal cyst (43/104) followed by simple serous cyst (25/104). (ijcrr.com)
Found1
  • No article was found for Cystadenocarcinoma, Serous and TERT[original query] . (cdc.gov)
Case report1
  • Mrad K , Driss M , Abdelmoula S , Sassi S , Hechiche M , Ben Romdhane K . Primary broad ligament cystadenocarcinoma with mucinous component: a case report with immunohistochemical study . (autopsyandcasereports.org)
Treatment1
  • Improper treatment, such as marsupialization, internal Roux-en-Y drainage, or percutaneous drainage and alcoholization, is associated with almost certain recurrence. (medscape.com)
Present1
  • The present case is the largest appendiceal cystadenocarcinoma ever reported. (biomedcentral.com)
Adenocarcinoma2
  • Isoprenaline and aminophylline may not take the drug is poorly absorbed orally and as injection 160 mg/ml for injection, excessive irradiation of malignant ovarian tumors surface epithelial tumors serous cystadenoma serous cystadenocarcinoma mucinous cystadenoma mucinous adenocarcinoma endometrioid borderline epithelial tumor brenner tumor larger masses can be antagonised by adrenaline. (ceu.edu)
  • According to recent study results, MASCs also mimic other salivary gland tumors, including adenocarcinoma, not otherwise specified (ANOS), mucoepidermoid carcinoma (MEC), and cystadenocarcinoma (CAC). (jpatholtm.org)
Pancreatic1
  • Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. (uci.edu)
Endometrioid1
  • Another research demonstrated that YAP1 is normally portrayed in serous/endometrioid cystadenocarcinomas extremely, and is favorably connected with individual prognosis (16). (pik-93.info)
Tumor4
  • The aim of this study was to assess the outcomes of the largest series of patients treated conservatively for a stage II or III serous borderline ovarian tumor. (nih.gov)
  • From 1969 to 2006, 41 patients were treated conservatively for an advanced-stage serous borderline ovarian tumor. (nih.gov)
  • All patients with serous cystadenocarcinomas and serum CA 125 values of 20-35 u/ml had residual tumor, and two-thirds of these cases had grossly visible disease. (elsevier.com)
  • Serous cystadenocarcinoma with inltrating cords of tumor cells with prominent dissolution of tumor. (tetratherapeutics.com)
Peritoneal2
  • More than 90% of fallopian tube cancers are serous adenocarcinomas, which are histologically indistinguishable from papillary serous ovarian carcinoma ( 4, 5 ), so they must be defined morphologically by the invasion of the peritoneal surfaces with minimal or no involvement of the ovaries ( 6 ). (aacrjournals.org)
  • Psammocarcinoma is a rare form of serous ovarian and peritoneal carcinoma, characterized by abundant psammoma bodies, invasiveness, and low-grade cytological features. (omeka.net)
Cystadenocarcinomas1
  • Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (bvsalud.org)
Benign2
  • In the cystadenomas and areas consisting of benign-appearing cells in the cystadenocarcinoma , CEA was localized to the luminal surfaces of the glandular cells appearing as thin linear stains. (lookfordiagnosis.com)
  • For patients with malignant ovarian disease, this study was limited to serous papillary adenocarcinomas and women with benign ovarian disease were limited to serous adenoma. (congresoendocrinologia2016.com)
HGSOC3
  • High-grade serous ovarian carcinoma (HGSOC) accounts for most ovarian cancer cases, and it is most frequently diagnosed at advanced stages. (aacrjournals.org)
  • High-grade serous ovarian carcinoma (HGSOC) is the most common type of ovarian cancer and is the cause of approximately 70% to 80% of all ovarian cancer deaths ( 2, 3 ). (aacrjournals.org)
  • Therefore, the aim of the present study was to comparatively examine expression of notable immune co‑stimulatory and co‑inhibitory receptors in order identify the most abundant receptors that could potentially serve as therapeutic targets to enhance immunotherapy response in high grade serous ovarian cancer (HGSOC). (spandidos-publications.com)
Malignant ovarian1
  • Nevertheless, the function of YAP1 as an oncogene hasn't yet been completely investigated in a big band of ovarian serous cystadenocarcinoma (OSC) sufferers, who take into account the biggest percentage of malignant ovarian cancers situations (17,18). (pik-93.info)
Cancer4
  • FOXM1 and RHNO1 are both amplified and upregulated in high-grade serous ovarian cancer (HGSC). (biorxiv.org)
  • Is Trametinib a New Standard for Low-Grade Serous Ovarian Cancer? (medscape.com)
  • En 11 annees (1er janvier 1998-31 decembre 2008) 9946 patientes ont ete operes dans notre servie dont 29 pour le cancer de l'ovaire soit 0;29. (bvsalud.org)
  • Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. (uams.edu)
Case1
  • The interactive module below presents a case of ovarian serous cystadenocarcinoma through pre- and post-operative contrast-enhanced CT as well as a 3D reconstruction. (medscape.com)
Article1
  • No article was found for Cystadenocarcinoma, Serous and KIR3DP1[original query] . (cdc.gov)
Type1
  • Serous carcinomas were the most commonly diagnosed histologic type for all anatomic sites. (aacrjournals.org)
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors - Full Text View - ClinicalTrials.gov
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors - Full Text View - ClinicalTrials.gov (clinicaltrials.gov)
TMEM158 promotes the proliferation and migration of glioma cells via STAT3 signaling in glioblastomas | Cancer Gene Therapy
TMEM158 promotes the proliferation and migration of glioma cells via STAT3 signaling in glioblastomas | Cancer Gene Therapy (nature.com)
Find Research outputs - Manipal Academy of Higher Education, Manipal, India
Find Research outputs - Manipal Academy of Higher Education, Manipal, India (manipal.pure.elsevier.com)
Simple Ovarian Cysts on Ultrasound Need No Further Monitoring
Simple Ovarian Cysts on Ultrasound Need No Further Monitoring (medscape.com)
Ovarian collision tumor consisting of sclerosing stromal tumor and mature cystic teratoma complicated with Meigs syndrome: A...
Ovarian collision tumor consisting of sclerosing stromal tumor and mature cystic teratoma complicated with Meigs syndrome: A... (spandidos-publications.com)
Serum vitamin D deficiency and risk of epithelial ovarian cancer in Lagos, Nigeria - ecancer
Serum vitamin D deficiency and risk of epithelial ovarian cancer in Lagos, Nigeria - ecancer (ecancer.org)
FFCP PHASE2:Hg19::chr11:112034803..112034824,- - resource_browser
FFCP PHASE2:Hg19::chr11:112034803..112034824,- - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr3:197205905..197205924,+ - resource_browser
FFCP PHASE1:Hg19::chr3:197205905..197205924,+ - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr10:128359255..128359269,- - resource_browser
FFCP PHASE1:Hg19::chr10:128359255..128359269,- - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE2:Hg19::chr6:71665623..71665630,- - resource_browser
FFCP PHASE2:Hg19::chr6:71665623..71665630,- - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr14:36989412..36989423,- - resource_browser
FFCP PHASE1:Hg19::chr14:36989412..36989423,- - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr10:12237820..12237834,- - resource_browser
FFCP PHASE1:Hg19::chr10:12237820..12237834,- - resource_browser (fantom.gsc.riken.jp)
MeSH Browser
MeSH Browser (meshb.nlm.nih.gov)
FFCP PHASE1:Hg19::chr10:75525304..75525312,+ - resource_browser
FFCP PHASE1:Hg19::chr10:75525304..75525312,+ - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr11:22647029..22647049,- - resource_browser
FFCP PHASE1:Hg19::chr11:22647029..22647049,- - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr19:1038526..1038570,+ - resource_browser
FFCP PHASE1:Hg19::chr19:1038526..1038570,+ - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr11:33890031..33890035,+ - resource_browser
FFCP PHASE1:Hg19::chr11:33890031..33890035,+ - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr17:42117687..42117722,- - resource_browser
FFCP PHASE1:Hg19::chr17:42117687..42117722,- - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr11:10715239..10715256,- - resource_browser
FFCP PHASE1:Hg19::chr11:10715239..10715256,- - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr12:122459724..122459737,- - resource_browser
FFCP PHASE1:Hg19::chr12:122459724..122459737,- - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr10:125853048..125853095,- - resource_browser
FFCP PHASE1:Hg19::chr10:125853048..125853095,- - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr10:63839926..63839931,- - resource_browser
FFCP PHASE1:Hg19::chr10:63839926..63839931,- - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr12:42983782..42983815,- - resource_browser
FFCP PHASE1:Hg19::chr12:42983782..42983815,- - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr17:39740611..39740628,+ - resource_browser
FFCP PHASE1:Hg19::chr17:39740611..39740628,+ - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr12:66026167..66026180,+ - resource_browser
FFCP PHASE1:Hg19::chr12:66026167..66026180,+ - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr12:123465218..123465275,+ - resource_browser
FFCP PHASE1:Hg19::chr12:123465218..123465275,+ - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE2:Hg19::chr11:112034761..112034772,- - resource_browser
FFCP PHASE2:Hg19::chr11:112034761..112034772,- - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr10:61005253..61005284,+ - resource_browser
FFCP PHASE1:Hg19::chr10:61005253..61005284,+ - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr10:101190374..101190429,- - resource_browser
FFCP PHASE1:Hg19::chr10:101190374..101190429,- - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr10:97149558..97149587,- - resource_browser
FFCP PHASE1:Hg19::chr10:97149558..97149587,- - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr10:93335091..93335099,- - resource_browser
FFCP PHASE1:Hg19::chr10:93335091..93335099,- - resource_browser (fantom.gsc.riken.jp)
FFCP PHASE1:Hg19::chr10:23983950..23983961,+ - resource_browser
FFCP PHASE1:Hg19::chr10:23983950..23983961,+ - resource_browser (fantom.gsc.riken.jp)